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Statement of Problem:  Over the last several decades the prevalence of pediatric hypertension 
has increased fourfold, thought to be partially attributable to the concurrent rise in pediatric 
obesity.  Hypertensive children are at increased cardiovascular disease risk as they often 
manifest other cardiovascular disease risk factors such as obesity, dyslipidemia, and insulin 
resistance.   Further, up to 40% have target organ damage in the form of left ventricular 
hypertrophy at initial diagnosis.  Left ventricular hypertrophy, a pathological remodeling of the 
heart thought to be secondary to increased left ventricular afterload as seen in hypertension, 
causes arrhythmias, heart failure and myocardial infarction in adults.  Its striking prevalence at 
initial diagnosis suggests that elevated blood pressure detection and hypertension diagnosis in 
children may be delayed or because other factors, specifically obesity, play a more substantial 
role in its development among hypertensive children.  
Methods:  We conducted two studies: 1) a pre-post evaluation of a quality improvement 
initiative to improve elevated blood pressure recognition among children and adolescents seen 
for primary care.  The intervention consisted of a one-time provider educational session and 
implementation of an ongoing real-time electronic medical record alert; and 2) a prospective, 
observational study of hypertensive children to investigate the association of obesity and 
obesity-related risk factors with the presence of left ventricular hypertrophy and with the 
change in left ventricular mass over a 12-month period of anti-hypertensive therapy.  
Results: We found that recognition of elevated blood pressure among patients seen for 
pediatric primary care was poor overall but increased from 12.5% pre-intervention to 42% 
during the intervention period (p<0.001).  Recognition was no different by educational session 
attendance status.  During both pre-intervention and intervention periods, systolic BP 
iii 
 
≥120mmHg was associated with greater recognition. However, the prevalence ratio (PR) was 
smaller in the intervention period:  intervention PR 1.3, 95% confidence interval (CI) 1.2 – 1.5 
(p<0.001) versus pre-intervention PR 2.4, 95% CI 1.4-3.9 (p=0.001).  Similar relationships were 
observed for other cardiovascular disease risk factors.  Acute care visit encounters were 
associated with decreased recognition in the intervention period (PR 0.6, 95% CI 0.5- 0.7; 
p<0.001).   
We also found a high prevalence of cardiovascular disease risk factors among children with 
hypertension:  51% were overweight/obese and 41% had left ventricular hypertrophy.  Children 
with LVH had greater BMI z-score and BMI percentile, higher serum uric acid level, a lower 
serum lipoprotein (a) level and a greater pro-B natriuretic peptide level than those without LVH.  
There was no difference in multiple measures of blood pressure between those children with 
and without LVH.  Children who were obese at both study visits experienced the greatest 
increase in LVMI over time: mean change in LVMI was 6.4 g/m2.7 (95% CI 2.4, 10.5) among those 
overweight or obese at each visit, vs. 0.95 g/m2.7 (95%CI -3.2, 5.1) among children who were of 
healthy weight at each visit (p=0.056).  Overweight/obese children with and without LVH at 
baseline demonstrated a larger increase in LVMI compared to healthy weight children.  Healthy 
weight children with LVH were the only ones with decreased LVMI over time. BMI z-score at 
baseline was positively associated with change in LVMI over time (β 4.08, 95% confidence 
interval 1.54, 6.61, p=0.002) during multivariable regression analyses adjusting for age, sex, 
race, and LVMI at baseline.  The association remained essentially unchanged after sequential 
adjustment for postulated mediating pathways between BMI z-score and LVMI with the 
exception of pulse pressure and serum aldosterone.  When added to the model, those two risk 
factors decreased the point estimate and p-value. 
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 Conclusion/Implications:  Elevated blood pressure in children is largely unrecognized, and 
those with minimal to no additional cardiovascular disease risk factors are least likely to be 
recognized in a primary care setting.  Real time electronic medical record alerts substantially 
increase provider recognition of elevated BP in children and hold considerable promise as a 
means to improve adherence to practice guidelines.  These alerts particularly aid in the 
recognition of elevated blood pressure among those not at obvious cardiovascular disease risk.   
However, the persistence of under-recognition of elevated BP in children highlights the need for 
additional strategies to further improve provider recognition.   
Hypertensive children referred for subspecialty care demonstrate not only a high prevalence of 
co-morbid cardiovascular risk factors at baseline, but an increase in both their prevalence and 
severity over time.   Most striking of these cardiovascular risk factors is the presence and 
substantial degree of overweight and obesity.  In fact, adiposity as determined by body mass 
index z-score was the greatest risk factor for left ventricular hypertrophy and change in LVMI 
over time.  None of the many measures of blood pressure assessed during this study were 
associated with the presence of LVH or with the change in LVMI over time.  And, two risk factors 
potentially modified by diet - pulse pressure, a marker of intravascular volume, and serum 
aldosterone, a hormonal regulator of blood pressure – appeared to be the most important 
partial mediators of the relationship between adiposity and change in LVMI.   These findings 
support the overwhelming public health concern regarding the obesity epidemic and suggest 
that greater emphasis on overweight and obesity prevention and treatment should be made 
among hypertensive children.   
Future Directions:  Our work emphasizes the substantial prevalence of cardiovascular disease 
risk factors among children and adolescents.  It also suggests that current population estimates 
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of the burden of pediatric hypertension may underestimate the true prevalence as a substantial 
number of children with elevated blood pressure are unrecognized in a primary care setting.  A 
common underlying theme to this increased CVD risk is overweight and obesity.  Despite 
providing standard of care guidance on weight loss and adherence to a heart healthy diet, the 
children in our study became more overweight/obese and demonstrated an increase in number 
and severity of CVD risk factors over a year of observation.  Enhanced preventive and 
therapeutic strategies targeting overweight and obesity in children holds significant promise as 
we work towards primordial and primary prevention of adult cardiovascular disease.  Further 
research should test innovative interventions designed to assist youth with adherence to a heart 
healthy lifestyle and determine the effect of these interventions on cardiovascular disease risk 
factors.   
 
 
Academic Advisor: Marlene R. Miller, M.D., M.Sc. 
Thesis Mentor: Edgar R. Miller III, M.D., Ph.D. 


















To my husband, Nick,  
And our three inquisitive and curious children,  
Tom, Nate and Lexi 
Thank you for being my constant inspiration 

















They say “it takes a village”.  While generally referring to raising children, this concept 
highlighting the importance of community support perfectly describes how I was able to 
successfully complete this thesis.  From the moment I informed my parents that I was pursuing 
medicine as a career to the moment I told my husband I wanted to obtain my PhD (while 
continuing to expand our family), I have been met with nothing but support and 
encouragement.  I have been humbled by the generosity of others - generosity of time, of 
kindness, of understanding – as I pursued this higher education.  This came from people in all 
aspects of my life: my family, my friends, my mentors and advisors, my thesis committee, my 
colleagues and the wonderful members of the Division of Pediatric Nephrology.  Without the 
tireless support of these wonderful individuals, I would not have been able to complete my 
research or this thesis.  I therefore dedicate this work to my “village”. 
I would like to thank my research mentors, Drs. Pete Miller, Larry Appel and Barbara 
Fivush, for all of their time and for imparting the wisdom that has and will continue to shape my 
career.  Possibly more than that, I would like to thank them for being incredible models of how 
to be prominent members of the scientific community while also achieving the ultimate Holy 
Grail - Work-Life Balance.   
To my Advisor, Dr. Marlene Miller, I would like to thank you for your endless guidance as 
I navigated my way as a student again.  I am extremely grateful for your interest in my career as 
a whole and for your willingness to advise and mentor me on topics not related to my degree.  
To my thesis committee, thank you for your availability, support, time and investment in me and 
my research.  I have learned a great deal from all you.   
viii 
 
To my colleagues, I cannot thank you enough for your flexibility, camaraderie, 
collegiality and friendship.  When I told you of my plans to pursue this degree, and how this 
would require a significant inflexibility to my call and clinic schedule, not a single one of you 
gave it a second thought.  You have allowed me to flourish in my role as a student, to go “all in” 
and immerse myself in my studies and research, and I will be forever grateful to all of you for 
that. 
To my research assistant, Sara Boynton, words cannot express how immensely 
appreciative I am of everything you have done for me.  Your tireless work ethic, attention to 
detail and knowledge of the inner workings of the Johns Hopkins research structure is 
unparalleled.  I am so lucky to have had the chance to work with you and learn from you.  Thank 
you. 
To the amazing staff in the Division of Pediatric Nephrology, specifically Shirl Wood, 
Barbara Case and Rene Shumate: your support and willingness to go above and beyond for me 
in any and everything is bar none.  I cannot thank you enough for that, nor for the many needed 
humor breaks.  You are amazing individuals and I am blessed to work with you every day. 
To my parents, Mike and Dot McLoughlin, your unconditional love, unwavering 
confidence in me and unquestioning support of every seemingly hair-brained scheme I have 
presented you with has allowed me to be fearless in my pursuits.  You continue to inspire and 
encourage me to this day.  I can only hope to be half as good of a parent to my own children as 
you were to me and my brothers, Mike and Bob. 
And, finally, to my husband Nick – you have sacrificed much and been rewarded with 
little during this journey of mine.  You have taken on more than your fair share of responsibility 
for most everything these last few years without a single complaint.  You have stayed up late 
ix 
 
with me, taken the kids out of the house so I could do my “work” and done more pick up/drop 
offs and laundry than anyone should have to do.  You are my rock and I could never have done 
this without you.  I dedicate this work most of all to you and our three beautiful children – Tom, 
Nate and Lexi.  Thank you for being you, for keeping me grounded and for reminding me what is 























Table of Contents 
Abstract………………………………………………………………………………………………………………………………………ii 
Preface…………………………………………………………………………………………………………….………………………..vii 
Table of Contents…………………………………………………………………………………….………………………………….x 
List of Tables…………………………………………………………………………………………………………………………..…xii 
List of Figures……………………………………………………………………………………………………………………….….xiii 
Chapter 1: Introduction………………………………………………….………………………..…………………………………1 
Chapter 2: Pediatric Hypertension……………………………………………………………………………………………..5 
Case Study……………………………………………………………………………………………………………………..5 
Introduction/Definition....……………………………………………………………………………………….……..6 













































List of Tables 
Table 1: Comorbid Conditions Requiring a BP Measurement in Children < 3 Years of Age…………8 
Table 2: Differential Diagnosis of Hypertension among Children, by Age….…………………………..…11 
Table 3: Symptoms That May be Suggestive of Underlying Etiologies of Pediatric 
Hypertension……………………………………………………………………………………………………………………………15 
Table 4: Physical Examination Findings Suggesting Hypertension Etiology..…………………………....16 
Table 5: Initial Laboratory and Imaging Evaluation for All Children with Confirmed 
Hypertension……………………………………………………………………………………………………………………………17 
Table 6: Additional Tests to Determine Secondary Causes of Hypertension…………….………………19    
Table 7: Oral Medications for the Treatment of Pediatric Hypertension……………….…………………21 
Table 8: Characteristics of Encounters with Recognized Elevated Blood Pressure, Pre-
Intervention and Intervention Periods……………………………….…………………………………………………….44 
Table 9: Prevalence of Recognized Elevated Blood Pressure in the Pre-Intervention and 
Intervention Periods Stratified by Patient, Clinic and Provider Characteristics…………………………46 
Table 10:  Prevalence Ratio (PR) of Recognized Elevated Blood Pressure during the Pre-
Intervention and Intervention Periods by Month, Unadjusted and Adjusted for Education Session 
Attendance………………………………………………………………………………………………………………………………48 
Table 11a: Baseline Characteristics of 49 Hypertensive Children and Adolescents with and 
without Left Ventricular Hypertrophy – Demographics, Anthropometrics and Obesity Related 
Laboratory Measurements……………………………………………………………………………..……………………….67 
Table 11b: Baseline Clinic Blood Pressure, 24-hour Ambulatory Blood Pressure and Related 
Measures in Children with and without Left Ventricular Hypertrophy…………………………………….69 
Table 12: Association of Baseline Characteristics, Change in Baseline Characteristics and Change 
in Left Ventricular Mass Index, Adjusted for Age, Sex and Race………………………………….…………..71 
Table 13: Association of Baseline Body Mass Index z-score with Change in Left Ventricular Mass 







List of Figures 
Figure 1: Flow Diagram of Included Encounters and Provider Recognition in the Intervention 
Period……………………………………………………………………………………………………………………………………….42 
Figure 2: Percent of Elevated Blood Pressure Measurements Recognized by Providers during the 
Pre-Intervention and Intervention Periods………………………………………..……………………………………..42  
Figure 3: Prevalence Ratios of Elevated Blood Pressure Recognition by Various Characteristics 
during the Pre-Intervention and Intervention Periods………………………………………………….…….……43 
Figure 4: Mean Change in Left Ventricular Mass Index by Weight Status at Baseline………………65 
Figure 5: Mean Change in Left Ventricular Mass Index by Weight and Left Ventricular 




Chapter 1: Introduction 
Hypertension in children is on the rise.  Over the last 30-40 years pediatric hypertension 
in the United States has increased fourfold1, 2.  Currently, up to 4.5%, or 3.34 million children in 
the United States, are diagnosed with this condition3, 4.  Recent American Heart Association 
Heart Disease and Stroke statistics suggest the number affected may be higher, with up to 15% 
of adolescents having abnormal blood pressure when defined as  >120/805.   
While the reason for the increase in pediatric hypertension is not entirely clear, many 
consider it to be a consequence of the coincident obesity epidemic.  Since 1980 the prevalence 
of obesity among children and adolescents has almost tripled6.  Thirty-two percent of children in 
the United States are now overweight or obese7.  Further, when only considering this group of 
at risk children, the estimated proportion of children afflicted with hypertension is much 
greater, ranging from 20-47%8. 
While the hypertension burden and resulting sequelae in adults are widely known, the 
prevalence of hypertension and target organ damage in children is only just beginning to be 
recognized.  Pediatric hypertension, particularly primary hypertension, is almost exclusively 
clinically silent.  However, up to 40% of hypertensive children have left ventricular hypertrophy, 
a pathological remodeling of the heart thought to occur in response to an increased left 
ventricular afterload, at initial diagnosis of hypertension3, 9, 10.  Left ventricular hypertrophy is 
also clinically silent in childhood, but is a well-established precursor for arrhythmias and heart 
failure in adults.11  Its striking prevalence at initial diagnosis suggests that elevated blood 
pressure detection and hypertension diagnosis in children may be delayed or because other 
factors, specifically obesity, play a more substantial role in its development. 
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There have been several landmark studies demonstrating the progression, or tracking, 
of blood pressure from childhood to adulthood12, 13.   In addition, children who are hypertensive 
have a high likelihood of becoming adults who are hypertensive, and this likelihood increases 
with the co-morbid presence of obesity and/or left ventricular hypertrophy.  With heart disease 
the leading cause of death in the United States14, decreasing the prevalence of hypertension and 
ultimately left ventricular hypertrophy in at risk children would greatly aid in decreasing adult 
cardiovascular disease mortality. 
Essential to diminishing the amount of hypertension and target organ damage found in 
children is the early identification of elevated blood pressure and diagnosis of hypertension.  
Findings from the Young Finns Study15 reveals the importance of early diagnosis: the greater the 
number of ideal cardiovascular health metrics present in childhood, the lower the risk of 
hypertension and risk for atherosclerosis later in life.  This applies to young adults as well, with 
the Coronary Artery Risk Development in (Young) Adults (CARDIA) study demonstrating that a 
greater number of healthy behaviors in early adult life can result in a lower cardiovascular 
disease risk profile in middle age16.   
This rationale  - that early identification of a preventable and treatable condition could 
lead to increased health and decreased cardiovascular disease mortality - has led several 
prominent medical organizations including the American Heart Association, the National High 
Blood Pressure Education Program, National Heart Lung and Blood Institute, the European 
Society of Hypertension, and the American Academy of Pediatrics to publish guidelines 
emphasizing the importance of blood pressure screening in childhood3, 17-20.  These guidelines 
recommend measuring blood pressure in all children ages 3-17 years at least once during every 
health care episode to screen for hypertension.   
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Despite these recommendations calling for blood pressure screening at all health care 
encounters, on average, health care providers measure blood pressure only two-thirds of the 
time during well-child visits and one-third of the time during sick visits21.  In addition, because of 
the complex steps required to determine normal blood pressure values in children, elevated BP 
readings are only recognized 15% of the time22, 23.  If providers are not consistently measuring 
blood pressure and are not recognizing when it is elevated, then our assessment of the burden 
of pediatric hypertension is likely modest at best.   
To improve the identification of hypertensive children, providers need better tools to 
assist with identification of elevated blood pressure.  In addition, once children are diagnosed 
with hypertension providers need better methods to identify those at greatest cardiovascular 
disease risk.  Previous work has shown that degree of blood pressure elevation does not predict 
which child with hypertension may or may not have left ventricular hypertrophy9.  Several cross-
sectional studies and some longitudinal studies in primarily white children have suggested 
adiposity, not blood pressure, to be most associated with left ventricular hypertrophy9, 24-27.  If 
adiposity is indeed more associated with left ventricular hypertrophy, then practice guidelines 
would need to place more emphasis on both prevention of obesity among children and 
adolescents with hypertension and treatment of obesity among these children when present 
alongside left ventricular hypertrophy.     
With this background in mind, the goals of this thesis research were to 1) conduct a pre-
post evaluation of a quality improvement initiative to improve elevated blood pressure 
recognition among children and adolescents seen for primary care.  Our intervention consisted 
of a one-time provider educational session and implementation of an ongoing real-time 
electronic medical record alert; and 2) conduct a longitudinal, prospective observational study 
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of hypertensive children to investigate the association between obesity and obesity-related risk 
factors with the presence of left ventricular hypertrophy and with the change in left ventricular 
mass over a 12-month period of anti-hypertensive therapy.   
Improving elevated blood pressure recognition will enhance our ability to identify 
children at increased cardiovascular disease risk.  It will also augment our primordial and 
primary preventive efforts which are the underpinnings of the contemporary strategy to prevent 
cardiovascular disease as recommended by the American Heart Association28.  Further, detailing 
the association of adiposity with left ventricular hypertrophy among hypertensive children will 
assist us in focusing our treatment efforts.   Ultimately, improving our ability to identify and 
adequately risk stratify youth at increased cardiovascular disease risk will allow us to optimize 
the care we provide to our pediatric patients and ultimately decrease the cardiovascular disease 
morbidity and mortality in adults. 
Published in part in Pediatric Nephology: Brady, TM, Redwine, KM, Flynn, JT; for the American 
Society of Pediatric Nephrology. Screening Blood Pressure Measurement in Children: Are We 













Chapter 2: Hypertension 
Objectives: 
After completing this article, readers should be able to:  
1. Define hypertension in children, and be familiar with the approach to the diagnosis of 
hypertension. 
2. Recognize important signs and symptoms associated with hypertension and its 
sequelae, and formulate an appropriate differential when presented with a 
hypertensive child or adolescent. 
3. Initiate an appropriate work up, and know when to refer to subspecialty care. 
4. Prescribe both non-pharmacologic and pharmacologic anti-hypertensive therapy to 
hypertensive children, and be familiar with the various classes of anti-hypertensive 
medications available. 
Case Study 
Jennifer is a 12-year-old girl who plays field hockey and is in your office for a sports physical.  
She reports feeling well, denies any complaints and has no significant past medical history.  She 
is not taking any medications.  Family history is reviewed and is unchanged, significant only for 
grandparents on both sides of the family with hypertension, and a paternal grandfather who 
had a myocardial infarction at 60 years of age, and is still living.  She is a straight “A” student, 
and lives at home with her parents and 2 brothers who are healthy.  Review of symptoms 
significant for menarche several months prior, otherwise negative. 
Physical examination shows her height and weight to be both at the 50th percentile.  Blood 
pressure was 136/82 initially in triage; repeat was 132/78 by the same automated oscillometric 
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device five minutes later.  She is a normal appearing, young girl who is comfortable and in no 
apparent distress.  The rest of her physical exam is well within normal limits.  You repeat her 
blood pressure by manual auscultation and obtain a blood pressure measurement of 128/77. 
Introduction 
While once only affecting 1% of all children, pediatric hypertension is on the rise, now affecting 
almost 5% of all children3.  One possible explanation for this fourfold increase in prevalence over 
the last several decades is the concurrent rise in pediatric obesity, which currently affects 17% 
of US children and adolescents29.  Blood pressure increases with increasing body mass index, 
which explains the staggering 20-47% of obese children who are hypertensive8.  This significant 
increase makes it much more likely that pediatric providers will find themselves caring for 
hypertensive children, heightening the need for proper recognition, evaluation and treatment in 
the primary care setting.   
Definition 
Pediatric hypertension is defined as the sustained elevation of either the systolic or diastolic 
blood pressure at or above the 95th percentile BP for a child’s age, sex and height percentile.   
Essential to this definition is the presence of sustained BP elevation, which is why all elevated 
blood pressure measurements should be confirmed by repeated measurements conducted by 
manual auscultation, with the average of all measurements used to determine the category of 
HTN.  The severity of the elevation will dictate how many measurements are needed prior to 
diagnosis and work up30.  In 2004, Pediatrics published updated sex-, age- and height percentile-
specific 50th, 90th, 95th and 99th percentile systolic and diastolic BPs for children aged 1 to 17 
years3.  These normative values were compiled from over 60,000 healthy children in the United 
States, based on their first auscultatory blood pressure measurement obtained during 
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screening, and should be used to classify children into one of the following blood pressure 
categories:    
1. Normal Blood Pressure: Both systolic and diastolic BPs are less than the 90th percentile 
or less than 120/80, whichever is lower. 
2. Prehypertension: Systolic and/or diastolic BP is between the 90th percentile and the 
95th percentile, or between 120/80 and the 95th percentile if 120/80 happens to be 
higher than the reported 90th percentile for the individual child based on his/her age, 
sex, and height percentile. 
3. Stage I Hypertension: Systolic and/or diastolic BP between the 95th percentile and the 
99th percentile + 5 mmHg  
4. Stage II Hypertension: Systolic and/or diastolic BP above the 99th percentile + 5 mmHg  
Adolescents and young adults aged 18-21 years of age should be classified according to the 
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC-7) recommendations: 
1. Prehypertension: Systolic and/or diastolic BP ≥ 120/80 and ≤ 139/89 
2. Stage I Hypertension: Systolic and/or diastolic BP ≥ 140/90 and ≤ 159/99 
3. Stage II Hypertension: Systolic and/or diastolic BP ≥ 160/100 
When to screen for hypertension 
All children three years of age and older should have their blood pressure measured during each 
physician visit, whether the visit is for well child care, urgent care, or emergency care, at a 
minimum of once yearly.  In addition, children less than three years of age should also have their 
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blood pressure measured at each visit if they have a comorbid condition that places them at 
increased risk for hypertension (Table 1).   
Table 1: Comorbid Conditions Requiring a BP Measurement in Children < 3 Years of Age  
History of prematurity Solid organ transplant 
History of low birth weight/NICU stay Malignancy or Bone Marrow Transplant 
(BMT) 
Congenital heart disease Taking meds known to increase BP 
Recurrent UTI, hematuria, proteinuria  Presence of systemic illness associated with 
HTN 
Known renal disease or genitourinary 
abnormalities 
Evidence of increased intracranial pressure 
Family history of congenital kidney disease  
Table adapted from The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children 
and adolescents. Pediatrics 2004;114:555-763. 
Particular attention should be given to children with conditions such as diabetes mellitus, 
chronic kidney disease, history of Kawasaki disease (with or without current coronary artery 
aneurysms), kidney or heart transplantation, chronic inflammatory diseases, HIV and nephrotic 
syndrome as they are at increased cardiovascular risk.  As such, in addition to regular blood 
pressure measurement, they should have additional cardiovascular risk factor assessment 
conducted at health care encounters.  
Any child with a blood pressure measurement at or above the 90th percentile (or at or above 
120/80 if this is greater than the 90th percentile for age) should have their BP re-measured at 
that visit.  The average of three measurements obtained by manual auscultation should be 
recorded, and the child should be “staged” as defined above.  This staging and the 
presence/absence of symptoms will dictate plans for future follow up: 
An average BP in the Pre-hypertensive range:  These children should be considered pre-
hypertensive, and should be followed closely due to their increased risk of developing sustained 
hypertension.  They should be counseled on weight management, if indicated, and should be 
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given activity and the Cardiovascular Health Integrated Lifestyle Diet-1 (CHILD-1) 
recommendations (see section below on non-pharmacological therapy)30.  Pre-hypertensive 
children should have a follow up appointment in 6 months to reassess blood pressure.  
An average BP in the range of Stage I hypertension:  If the child is asymptomatic, have him/her 
return for repeat BP measurements on two additional occasions, 1-2 weeks apart, in the same 
manner.  If Stage I hypertension is confirmed by averaging all BP measurements obtained, 
perform evaluation within one month.   If the child is symptomatic, more immediate referral to 
a pediatric hypertension specialist for initiation of evaluation and treatment is indicated.  
An average BP in the range of Stage II hypertension:  If the child is asymptomatic, he/she should 
undergo evaluation and treatment within 1 week.  If symptomatic, the child should be referred 
immediately to the emergency department or an inpatient facility for care.      
Pediatric hypertension is largely asymptomatic, however children may initially present in 
hypertensive crisis with severely elevated blood pressure and symptoms ranging from nausea 
and vomiting to ataxia, mental status changes, seizures and coma or with symptoms related to 
the underlying etiology of their hypertension.  In addition, some children may experience 
anxiety during evaluations which may cause elevated BPs that are in the hypertensive range, yet 
when monitored in their home environment are in the normal range.  This phenomenon of 
“white coat” hypertension can be diagnosed with a 24-hour ambulatory blood pressure monitor 
that obtains many BP measurements taken in a child’s home environment.  Children with white 
coat hypertension should also be considered at increased risk for the development of sustained 
hypertension and as such should be followed every 6 months31-33     
Proper Blood Pressure Measurement 
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To identify and diagnose a child with hypertension, one must use proper technique when 
measuring blood pressure.  Proper technique begins with applying the correct size cuff to a 
child’s bare arm, and ensuring that his/her arm, feet and back are supported, with the cubital 
fossa positioned at heart level.  To determine the correct cuff size, measure the cuff bladder 
(felt inside the outer packaging) to the child’s arm.  The right size cuff will have a bladder width 
that is at least 40% of the child's mid-arm circumference and a bladder length that encircles 80-
100% of the mid-arm circumference.  When in doubt, choose a larger cuff because a too-small 
cuff may result in artificially elevated blood pressures. 
After the child has been resting for five minutes: 
1. Locate the child’s radial pulse, quickly inflate the sphygmomanometer to 60 mmHg and 
then slowly continue to inflate in increments of 10 mmHg until the pulse disappears   
2. Note the Peak Inflation Level, which is the value at which the pulse disappears + 30 
mmHg  
3. Deflate the cuff and after 30 seconds inflate the sphygmomanometer to the Peak 
Inflation Level  
4. Deflate by 2-3 mmHg/second to a level that is 10 mmHg lower than the last Korotkoff 
sound (K5). 
a. Systolic BP = Onset of Korotkoff sounds (K1) 
b. Diastolic BP = Disappearance of Korotkoff sounds (K5) 
All blood pressure elevations (systolic or diastolic BP ≥ 90th percentile or ≥ 120/80) should be 
confirmed by this technique rather than by an automated device.  Automated, or oscillometric, 
devices (such as the Dynamap), while useful as screening tools, can provide inaccurate blood 
pressure measurements because they do not directly measure blood pressure, but instead 
estimate the systolic and diastolic blood pressure based on the point of maximal oscillation (the 
mean intra-arterial pressure) during cuff deflation.  The algorithms utilized to determine these 
values vary from device to device, leading to non-uniformity of measurement across devices.  
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Devices that automatically inflate to 30 mmHg above the previous reading can influence each 
subsequent blood pressure reading.  These limitations, and the fact that the normative values 
that make up the reference tables were obtained via auscultation, form the basis for the 
recommendation that all blood pressure elevations must be confirmed by manual auscultation. 
Initial Evaluation 
All children diagnosed with hypertension should undergo an evaluation to investigate for 
secondary causes of hypertension.  While primary hypertension is on the rise, and is the most 
common cause of hypertension among adolescents, secondary hypertension is common enough 
to warrant investigation, particularly in younger children and those with Stage II HTN at 
presentation (Table 2).   
Table 2: Differential Diagnosis of Hypertension among Children, by Age. 
Age Range Etiology Most common secondary causes 
Birth to 1 year Secondary (99%) 
Cardiac: 
- Coarctation of Aorta 
- Patent ductus arteriosis 
Renal: 
- Renovascular defect 
- Renal parenchymal disease 
Pulmonary: 
- Bronchopulmonary dysplasia 
Neurologic: 
- Intraventricular hemorrhage 
- Pain 
Neoplasia 
- Wilms tumor 
- Neuroblastoma 
Endocrine 
- Congenital adrenal hyperplasia 
- Hyperaldosteronism 
- Hyperthyroidism 





- Renal parenchymal disease 




- Coarctation of Aorta 
Urologic: 
- Reflux Nephropathy 
Endocrine 








Age 12 - 18 years 
 
Primary (85-95%) 
Secondary (5-15%) Same causes as for 1-12 yrs 
 
The initial evaluation should start with a focused history and physical examination.  In addition 
to obtaining a complete review of systems to help narrow the differential diagnosis (Table 3 
below), particular attention should be paid to the past medical history (including birth history), 
current medications, family history and social history. 
When obtaining the past medical history, it is important to inquire about any prior diagnosis or 
treatment of hypertension, and any recent discontinuation of antihypertensive medications, as 
beta-blockers and alpha-adrenergic agonists can cause severe rebound hypertension if 
discontinued abruptly.  It is also important to determine if the child has any of the following co-
morbid conditions or syndromes associated with hypertension: 
Co-morbid conditions: diabetes mellitus, thyroid disease, Cushing syndrome, systemic lupus 
erythematosis/other rheumatologic disorder   
Syndromes: 
Williams syndrome – associated with supravalvular aortic stenosis, mid-aortic syndrome, renal 
artery stenosis, renal anomalies 
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Turner syndrome - associated with coarctation of the aorta, renal anomalies, idiopathic 
hypertension 
Tuberous sclerosis - associated with coarctation of the aorta, renal artery stenosis, brain tumors 
Neurofibromatosis – associated with essential and renovascular hypertension 
Polycystic kidney disease, both autosomal recessive and autosomal dominant variants   
Prior history of urinary tract infections or unexplained fevers may suggest chronic pyelonephritis 
and renal cortical scars and/or reflux nephropathy.  A recent or relatively remote streptococcal 
infection of the pharynx or skin, or exposure to enterohemorrhagic E.coli, may indicate a 
resolving/resolved post-infectious glomerulonephritis or hemolytic uremic syndrome, 
respectively. Henoch-Schonlein purpura can be associated with persistent renal manifestations, 
including hypertension, even after initial complete resolution of symptoms.  Previous 
hospitalization(s) may reveal information on systemic illnesses, exposure to nephrotoxic 
medications or evidence of renal injury. Recent injuries should be assessed, as renal or 
neurologic trauma could lead to hypertension as well as associated pain.      
Because prematurity and low birth weight are associated with decreased nephron endowment 
and hypertension, and umbilical catheter placement can lead to renal artery stenosis and renal 
vein thrombosis, a detailed birth history should also be obtained.   
A thorough review of both prescribed and over-the-counter medications may reveal the 
following possible causes for elevated blood pressure: 
- Steroids 
- Decongestants/cold preparations  
- Nonsteroidal anti-inflammatory medications 
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- Herbal medications/supplements  
- Oral contraceptive pills 
- Anti-hypertensive medications (Recent discontinuation of these medications) 
- Beta-adrenergic agonists/theophylline  
- Erythropoietin 
- Cyclosporine/tacrolimus  
- Attention deficit disorder medications  
The family history can be helpful in determining etiology, particularly for children with 
monogenic forms of hypertension (such as Liddle Syndrome, Gordon Syndrome and Apparent 
Mineralocorticoid Excess) and renal disease, and can also help with risk stratification.  As 
described in the recent Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk 
Reduction in Children and Adolescents30, a positive family history of coronary heart disease in a 
male relative (father, grandfather, sibling or uncle) younger than 55 years or in a female relative 
(mother, grandmother, sibling or aunt) younger than 65 years is an independent risk factor for 
cardiovascular disease.  This risk is inversely related to the age at the time of event.  Children 
with this family history should be considered at increased cardiovascular risk.  Social history 
should focus on the following: Sexual activity (pregnancy, preeclampsia); Diet (consumption of 
caffeine, licorice, sodium, nutritional supplements); Smoking/drinking/illicit drug history 
(nicotine, cocaine, amphetamines, anabolic steroids, phencyclidine (PCP), MDMA (ecstasy)); 
level of physical activity (obesity); Sleep history (snoring, daytime somnolence, difficulty 





Table 3: Symptoms That May Be Suggestive of Underlying Etiologies of Pediatric Hypertension    
Organ System Possible Symptoms Potential Diagnoses   








Fatigue       
Thyroid disease 
Pheochromocytoma 






















Polycystic kidney disease 
Wilms Tumor 
Kidney stones 
Cardiovascular Chest pain 
Shortness of breath          
Palpitations 
Claudication  
Coarctation of the aorta 




Joint or muscle pain 
Fever 
Weight change  
Systemic Lupus Erythematosis 






Increased intracranial pressure 
Guillain-Barré syndrome 
 
Gynecologic Last menstrual period Pregnancy 
Pre-eclampsia 
 
After eliciting a detailed history, the evaluation should then progress to a detailed physical 






Table 4: Physical Examination Findings Suggesting Hypertension Etiology 
 Findings Possible etiologies 
Anthropometrics 





Chronic renal disease, 
endocrine disease, other 
chronic diseases 
 Obesity Primary hypertension, Cushing 
syndrome (also associated 
with short stature) 
Vital signs 
Blood pressure (4 limb)  
 
Lower BPs in lower 
extremities compared to 
upper extremities 
 
Coarctation of the aorta 
 









Fluid overload or edema 
 
Renal or heart failure 
 Moon facies Cushing’s syndrome, steroid 
use 
 Elfin facies William’s syndrome 
 Webbed neck, wide spaced 
nipples, short stature 
Turner’s syndrome 
 Pallor, flushing, diaphoresis Pheochromocytoma 
HEENT 
Including fundoscopic exam 




 Retinal hemorrhage, exudates Hypertensive emergency, 
hypertensive retinopathy 
 Cotton wool spots, AV nicking Hypertensive retinopathy 
 Contusions, lacerations, 
palpable skull defect, 
hemotympanum 
Head trauma 
 Exophthalmos, thyromegaly Hyperthyroidism 
 Adenotonsillar hypertrophy Obstructive sleep apnea 
Cardiovascular Heart murmur, diminished 
femoral pulses 
Coarctation of the aorta, 
patent ductus arteriosis 
 Friction rub Systemic lupus erythematosis, 
collagen vascular disease 
Pulmonary Accessory muscle use, 
crackles, wheeze 
Heart failure, asthma, 
bronchopulmonary dysplasia 
Abdominal Hepatomegaly Heart failure 




 Mass Wilms tumor, neuroblastoma, 
pheochromocytoma 
 Palpable kidneys Polycystic kidney disease, 
urologic disease, mass 
Extremities Joint swelling  Systemic lupus erythematosis 
Neurologic  Altered mental status Hypertensive encephalopathy 
 Mood Anxiety, white coat 
hypertension 
 Weakness   Monogenic forms of 
hypertension, 
hyperaldosteronism 
Skin Cafe au lait spots, axillary 
freckling, neurofibromas 
Neurofibromatosis 




 Malar rash Systemic Lupus erythematosis 
 Palpable purpura Henoch-Schonlein purpura, 
vasculitis 
 
Following the history and physical exam, all children should undergo a laboratory and imaging 
evaluation, the details of which are listed in Table 5.  If this initial work up is negative in an 
older child with Stage I hypertension, particularly if their average blood pressure is close to the 
95th percentile, the child can be given a diagnosis of primary hypertension.  Younger children 
and those with more markedly elevated blood pressure (Stage II hypertension) should undergo 
further testing if the initial evaluation is unrevealing in order to exclude secondary causes for 
hypertension (Table 6). 
Table 5: Initial Laboratory and Imaging Evaluation for All Children with Confirmed 
Hypertension 
Lab or imaging test Result Possible etiology 




Occult renal disease, chronic 
urinary tract infections 
BUN and creatinine  
 





Electrolytes, serum calcium Hyper- or hyponatremia, 
hyper- or hypokalemia, 
hypercalcemia 
 
Endocrine or genetic forms of 
hypertension 




Fasting lipids Elevated total cholesterol, 
LDL, triglycerides, low HDL 
 
Evaluating for co-morbidity 
Fasting glucose Hyperglycemia Diabetes mellitus, steroid use 
 
Plasma renin activity Low or absent plasma renin 
activity  
Endocrine or genetic forms of 
hypertension 
 
Urine pregnancy test (all post-
menarchal females) 
 
Positive test Pregnancy, pre-eclampsia 
Renal and bladder ultrasound Mass Wilms tumor, neuroblastoma, 
pheochromocytoma 
 Arteriovenous malformation Arteriovenous malformation 
 Bilaterally small kidneys Chronic kidney disease 
 Discrepant kidney sizes 
(≥1.5 cm) 
Past perfusional insults, renal 
scar, renal artery stenosis, renal 
hypoplasia, renal vein 
thrombosis 
 Bilaterally large kidneys +/- 
cysts 
Cystic kidney disease 




obstructive kidney stone 
 Renal tubers Tuberous sclerosis 
 Congenital anomalies Horseshoe kidney, pelvic kidney 
 
Echocardiogram Cardiac abnormalities Coarctation of the aorta, 
congenital anomalies, heart 
dysfunction, pericardial 
effusion 







Table 6: Additional Tests to Determine Secondary Causes of Hypertension 
Test Purpose 
Urine toxicology screen 
 
Rule out illicit drug use 





Rule out pheochromocytoma 
Polysomnography 
 
Rule out obstructive sleep apnea 
24-hour ambulatory blood 
pressure monitoring 
 
Rule out white coat 
hypertension 
Renal arteriogram with venous 
renin sampling 
Rule out renal artery stenosis 
 
Treatment 
Once a child is diagnosed with hypertension and has undergone an evaluation, antihypertensive 
therapy should be initiated.  This therapy should include guidance on lifestyle modification and 
non- pharmacologic therapy.  All children should be counseled on the following heart healthy 
lifestyle: 
1. Weight loss if overweight 
2. For children 5 years of age or older: participate in at least 1 hour of moderate-to-
vigorous exercise (for example: jogging, baseball) every day of the week, and vigorous 
activity (for example: running, singles tennis, soccer) on 3 days per week.   
3. Decrease sedentary activities such as television watching, video and computer games to 
less than two hours per day 
4. Institute several dietary changes according to the Cardiovascular Health Integrated 
Lifestyle diet (CHILD-1) and Dietary Approaches to Stop Hypertension (DASH) eating 
plan30 such as: 
a. Increase intake of fresh vegetables, fruits, and low-fat dairy  
b. Reduce carbohydrate, fat and processed sugar intake 
i. For 4-18 year olds: aim for 10-30% of total calories to come from 
protein, 45-65% from carbohydrate, 25-30% from fat 
c. Limit/avoid sugar-sweetened beverages 
d. Encourage foods with high dietary fiber content (age + 5 = number of 
grams/day) 
5. Salt restriction 
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a. Initially recommend “no added salt” with the ultimate goal of achieving the 
current recommendation of 1.2 grams per day total for 4- to 8-year-olds and 1.5 
grams per day total for children 9 years of age and older3        
6. Smoking cessation, if applicable 
Children who have not experienced normalization of their blood pressure with the above 
interventions after 6 months should be started on anti-hypertensive medications.  In addition, 
children who initially present with secondary hypertension, symptomatic hypertension, left 
ventricular hypertrophy, hypertensive retinopathy or who have diabetes mellitus, should be 
started on anti-hypertensive medications at the time of diagnosis, while implementing the same 
lifestyle interventions.  The pharmacological agent chosen should be targeted to the underlying 
diagnosis, with attention being paid to existing co-morbidities.   
Unless contraindicated, initial therapy with either a calcium channel blocker or an angiotensin 
converting Enzyme (ACE) inhibitor could be considered, as these medications are well-tolerated, 
have a minimal side effect profile, and can be dosed once daily.  Beta-blockers, angiotensin 
receptor blockers and diuretics are also acceptable first line agents for the treatment of 
hypertension in children.  The lowest dose should be started, titrating to effect until the 
maximum recommended dose is achieved or until the patient experiences side effects.  At this 
point, if blood pressure is not controlled, an additional agent from another class should be 
added to the regimen in the same manner.   Table 7 lists the major classes of antihypertensive 



















angiotensin I to 




enzymes.    
 
Leads to a decrease 

















Lab monitoring at 
initiation and 


























Start: 0.07 mg/kg/dose once daily; 
Maximum start dose: 5 mg/dose; 
Maximum dose: 0.61 mg/kg/dose up 
to 40 mg/dose. 
ADULT dose range: Start dose: 10 
mg/dose once daily; Usual dose 
range: 20-40 mg/day; Maximum 
dose: 80 mg/day 
Enalapril 
Start: 0.08-0.1 mg/kg/day; Maximum 
start dose: 5 mg/day 
Maximum dose: 0.6 mg/kg per day up 
to 40 mg/day 
(Can be given QD or divided BID) 
ADULT dose range: Start dose: 2.5-5 
mg/dose once daily; Maximum dose: 
40 mg/day 



















Lab monitoring at 
initiation and 















Start: 0.7 mg/kg/dose once daily 
Maximum start dose: 50 mg once 
daily 
Maximum dose: 1.4 mg/kg/day up to 
100 mg once daily 
ADULT Start dose: 50 mg once daily; 

















Blocks the following 






Beta (1): Increased 
cardiac output and 
renin secretion 
Beta (2): Increased 
renin secretion 




Heart rate can be 
dose-limiting 
 




























Start dose: 1–3 mg/kg/day divided 
BID; 
Maximum dose: 10–12 mg/kg/day up 
to 
1200 mg/day divided BID 
ADULT Start dose: 
100 mg BID; increase by 100 mg/dose 
every 2–3 days to a Maximum dose of 
2.4 g/24 hr Usual dose range: 200–





















Heart rate can be 
dose-limiting 
 
Can cause:  
Contraindicated in 
asthma and heart 
failure (Non-
cardioselective 






Start dose: 1–2 mg/kg/day divided 
BID or TID; Maximum dose: 4 mg/kg/ 
day up to 640 mg/day divided BID or 
TID 
ADULT Start dose: 40 mg/dose given 







although at higher 

























Should avoid use 
in diabetics 
 
capsule once daily.   
Usual dose range:  160-320 mg once 
daily; Maximum dose: 640 mg/24 hr. 
Atenolol 
(Cardioselective (β-1> β-2) Blocker) 
Start dose: 0.5–1 mg/kg/day divided 
QD or BID; 
Maximum dose: 2 mg/kg/day up to 
100 mg/day divided QD or BID; 
ADULT start dose: 50 mg once daily; 





channels located on 
muscle cells.  Leads 


























Start dose: 0.1 mg/kg once daily; 
Maximum start dose: 5 mg daily; 
Maximum dose of 0.6 mg/kg/day up 
to 10 mg/day. 
Can also be divided BID. 
ADULT start dose: 5- 10 mg once 
daily; 













Blocker use may 
exacerbate 
Clonidine 
Start dose: 5–10 mcg/kg/day PO 

























intervals to 5–25 mcg/kg/day PO 
divided Q6 hr; Maximum dose: 25 
mcg/kg/day up to 0.9 mg/day; 
ADULT start dose: 0.1 mg BID; 
increase in weekly intervals by 0.1 
mg/day; Usual dose range:  0.1–0.8 
mg/day divided BID; Maximum dose: 
2.4 mg/day 
Diuretic Thiazides inhibit 
sodium and 
chloride 






transport in the 
thick ascending 
limb of the loop of 
Henle.    
Useful as add-
on therapy and 



















diuretics can lead 
to hyperkalemia 








anuria and hepatic 
coma 
Hydrochlorothiazide 
Start dose: 1 mg/kg/day once daily 
Maximum dose: 3 mg/kg/day up to 
50 mg/day given once daily 
ADULT start dose: 12.5-25 mg once 
daily; Maximum dose: 100 mg/day 
divided once daily or BID 
Furosemide 
Start dose: 0.5–2.0 mg/kg/dose, can 
be given once daily to BID; Maximum 
dose: 6 mg/kg/dose given once daily 
or BID;  
ADULT start dose: 20-80 mg/dose 
given Q6-12 hours; Maximum dose: 




































Start dose: 0.75 mg/kg/day divided 
Q6-12 hours; Maximum start dose: 
25 mg/dose; 
Maximum dose: 7.5 mg/kg/day up to 
200 mg/day; 
ADULT start dose: 10-50 mg/dose 
given Q6 hours; Maximum dose: 300 
mg/day  
Minoxidil 
Children < 12 years: 
Start dose: 0.2 mg/kg/day divided 
QD-TID; Maximum start dose: 5 
mg/day; 
Maximum dose: 50 mg/day divided 
QD-TID 
Children ≥ 12 years/ADULT: 
Start dose: 5 mg/day divided QD-TID; 
Usual dose range: 10-40 mg/day 
divided QD-TID; 









Below are recommendations for prescribing classes of antihypertensive agents for certain 
medical conditions. 
Diabetes 
 Consider: ACE inhibitors, Angiotensin receptor blockers (Offer renoprotection and can 
decrease proteinuria) 
 Avoid: Beta-blockers (Can mask signs/symptoms of hypoglycemia) 
Migraine headaches 
 Consider: Beta-blockers, Calcium channel blockers (May offer symptomatic 
improvement for migraine headaches while controlling blood pressure) 
Asthma 
 Avoid: Beta-blockers since contraindicated for asthma (Can cause bronchospasm) 
Kidney disease and/or proteinuria 
 Consider:  ACE inhibitors, Angiotensin receptor blockers (Offer renoprotection and can 
decrease proteinuria) 
Athlete 
 Avoid: Beta-blockers, diuretics (May negatively impact athletic performance) 
Sexually active female 
 Avoid: ACE inhibitors, Angiotensin receptor blockers (Teratogenic; recommend birth 
control methods) 
Obesity 
 Consider: ACE inhibitors, Angiotensin receptor blockers (May have beneficial effects on 
comorbidities such as diabetes and dyslipidemia) 
 Avoid: Beta-blockers, diuretics 
(Beta blockers can lead to weight gain, increased triglycerides and decreased high-
density lipoprotein cholesterol concentrations) 
(Diuretics can worsen insulin resistance and dyslipidemia.  They can also increase 
sympathetic system nervous system and renin activity, both of which are thought to be 
increased in obesity- related hypertension)  
 
The goal of anti-hypertensive therapy is achievement of normotension, defined as persistent 
systolic and diastolic blood pressures below the 95th percentile.  In children at increased 
cardiovascular risk (those with chronic kidney disease, diabetes mellitus, post heart or kidney 
27 
 
transplantation, history of Kawasaki disease, chronic inflammatory disease, HIV or nephrotic 
syndrome) or with end-organ damage (left ventricular hypertrophy or hypertensive 
retinopathy), the anti-hypertensive goal is lower.  These children should be treated to achieve 
systolic and diastolic blood pressures below either the 90th percentile, or 120/80, whichever is 
lower.   
Prognosis  
Children with hypertension should be followed closely to evaluate the effectiveness of 
prescribed anti-hypertensive therapy, and to reinforce medication adherence and heart healthy 
behaviors.  If available, blood pressure measurements obtained by a school nurse can be useful 
in titrating medication dosages between clinic appointments, and in monitoring therapy.  
Hypertensive children should also be intermittently screened for the development of end-organ 
damage in the form of left ventricular hypertrophy, hypertensive retinopathy and 
microalbuminuria.  Children with left ventricular hypertrophy at diagnosis should have a repeat 
echocardiogram completed 6-12 months after starting anti-hypertensive medications to ensure 
their left ventricular mass has decreased with therapy. Children without evidence of left 
ventricular hypertrophy at diagnosis should also undergo follow up echocardiography as left 
ventricular hypertrophy can develop relatively quickly, can be seen in children with presumably 
good blood pressure control and cannot be predicted by the severity of a child’s blood pressure 
elevation.  While often clinically silent in childhood, these forms of end-organ damage are 
associated with significant morbidity and mortality in adulthood.  The presence of any one of 
these entities signifies increased cardiovascular risk and the need for intensified anti-
hypertensive treatment to reverse these findings and prevent worsening cardiovascular disease.  
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Some children will require long-term anti-hypertensive therapy into adulthood to maintain 
normotension.  However, successful implementation of lifestyle modifications has been shown 
to be effective in lowering blood pressure in both children and adults, and can allow some 
children to avoid or discontinue pharmacologic treatment.  Children with primary, obesity 
related hypertension in particular may be able avoid or discontinue anti-hypertensive 
medications with lifestyle modifications.  Obese children have been shown to experience 
significant blood pressure reductions with salt restriction, and weight loss is particularly 
effective at lowering blood pressure.   
Children with secondary hypertension may experience normalization of blood pressure as their 
underlying disease process resolves, allowing them to discontinue medical therapy.  However, 
when a chronic underlying condition has led to a child’s hypertension, complete normalization 
of blood pressure is less likely and management may require long-term antihypertensive 
therapy and monitoring.   
Summary 
Based on the National High Blood Pressure Education Program (NHBPEP) Working Group on 
Children and Adolescents consensus, which was developed from the synthesis of all available 
scientific evidence (NHBPEP, 2004): 
• Pediatric hypertension is defined as an average of systolic OR diastolic blood pressure 
measurements at or above the 95th percentile BP for the child’s age, sex and height 
percentile.   
• All children three years of age and older who present for care – well child care, urgent 
care, emergency care – should have their blood pressure measured during each visit.  In 
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addition, some at risk children under three years of age should also have their blood 
pressure measured at each provider visit. 
• All children with confirmed hypertension should undergo a work up to rule out 
secondary causes.  The age of the child and the severity of the blood pressure elevation 
will dictate how extensive this work up should be. 
• Once a child is diagnosed with hypertension and undergone a work up, anti-
hypertensive therapy should be initiated: this includes lifestyle modification for all 
children and pharmacologic therapy for some children.   
 
This article was previously published in Pediatrics in Review:  Brady, TM.  Hypertension.  




Chapter 3: Real Time Electronic Medical Record Alerts Increase High Blood Pressure 
Recognition in Children 
 
Abstract 
Background/Objective: Pediatric hypertension is increasingly prevalent but remains largely 
unrecognized.  Strategies to increase recognition of elevated blood pressure (BP) will enhance 
prevention and control efforts.  We hypothesized that an electronic medical record (EMR) alert 
system would increase elevated BP recognition in a pediatric primary care setting.  
Methods: Quality improvement initiative to improve elevated BP recognition through 
implementation of an ongoing real-time EMR alert coupled with a one-time provider 
educational session.  Encounters of children 3-21 years of age with an elevated intake BP and no 
history of hypertension were included. Recognition was defined as provider documentation of a 
repeat BP; BP noted to be abnormal; or plan to repeat/evaluate BP.  
Results: Recognition increased from 12.5% to 42% (p<0.001) and was no different by 
educational session attendance status.  During both pre-intervention and intervention periods, 
systolic BP ≥120mmHg was associated with greater recognition. However, the prevalence ratio 
(PR) of recognition was smaller in the intervention period:  intervention PR 1.3, 95% confidence 
interval (CI) 1.2 – 1.5 (p<0.001) versus pre-intervention PR 2.4, 95%CI 1.4-3.9 (p=0.001).  Similar 
relationships were observed for other cardiovascular risk factors.  Acute care visit encounters 
were associated with decreased recognition in the intervention period (PR 0.6, 95% CI 0.5- 0.7; 
p<0.001).   
Conclusions: Real time EMR alerts substantially increase provider recognition of elevated BP in 
children and hold considerable promise as a means to improve adherence to practice guidelines.  
Still, under-recognition of elevated BP in children persisted. These results highlight the need for 




Over the last several decades, pediatric hypertension (HTN) has increased in prevalence, 
and its importance in the overall cardiovascular (CV) health of children has been emphasized19.  
In addition to being associated with atherosclerosis in childhood, pediatric HTN is one CV 
disease (CVD) risk factor that has known clinical implications in adulthood.  As a result, 
guidelines published in 20043 and 201119 highlight annual blood pressure (BP) measurement of 
all children three years and older as one of the key strategies for CV risk identification and 
reduction among children to decrease the burden and associated morbidity and mortality of 
CVD in adults19.     
Despite these guidelines, routine BP measurement21, provider recognition of elevated 
BP, and diagnosis of pediatric HTN all remain low.  We have previously shown that only 13% of 
elevated BPs measured in an urban academic pediatric primary care setting were recognized as 
elevated by providers22.  These results are similar to those obtained in a pediatric emergency 
department setting34 and in a large pediatric primary care setting23, 35.   
Recognizing the many demands faced by primary care providers, we hypothesized that 
real-time electronic elevated BP alerts during clinic visits would increase recognition of elevated 
BP by eliminating the cumbersome steps for proper classification – specifically, the steps of 
determining a child’s age- and sex-specific height percentile followed by determining their age- 
sex- and height percentile- specific BP cutoffs.   We also hypothesized that improving provider 
knowledge of guidelines would contribute to greater recognition.   To test these hypotheses, we 
implemented and evaluated a two component intervention: ongoing real-time electronic 





We conducted a pre-post evaluation of a quality improvement and education initiative 
designed to improve provider recognition of elevated BP in children.  The setting was an urban, 
academic primary care practice staffed by pediatric residents, adolescent medicine fellows, 
attending physicians, and nurse practitioners.  All acute and scheduled (well-child care and 
follow-up) encounters during the intervention period (1/1/09-6/30/09) and scheduled 
encounters during the pre-intervention period (1/1/06-6/30/06) of patients 3-21 years of age 
with an elevated intake BP were included.   
The pre-intervention and intervention periods were chosen to capture a different cohort 
of resident providers, target the same time of year to minimize the impact of resident training 
level, and occur soon after alert implementation.  Encounters were excluded if they were of 
children with a prior HTN diagnosis (n=105); if BP was <120/80 and no height information was 
recorded within the previous 6 months (n=15); or if the provider clinic note was missing (n=51).  
This study was approved by an institutional review board of Johns Hopkins University School of 
Medicine.   
Blood Pressure Measurement Protocol and Intervention 
In the practice, intake BP was measured via oscillometry by a nurse or a nursing 
assistant prior to the provider encounter.  All intake BPs, together with the patient’s height and 
weight, were immediately entered into the EMR and were available to providers at the start of 
the visit during both periods.  Pediatric guidelines for monitoring BP, which included 
age/sex/height percentile-specific BP norms3 were readily available in print and on-line.   
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In September 2008, a real-time electronic alert was incorporated into the existing EMR 
to notify providers when an intake BP was elevated.  All elevated BPs (≥90th percentile for 
age/sex/height percentile19 or ≥120/80) generated an EMR alert that the BP was elevated and 
should be repeated.  This was a hard stop and could only be reconciled by entering: “provider 
needs to obtain manual repeat” or “manual repeat completed” with the additional BPs entered 
in the EMR at that time.  All BPs obtained by the nursing staff and all responses entered were 
immediately visible to the provider in the EMR.   
In addition to this alert, a 30-minute educational session reviewing current BP 
measurement guidelines and HTN evaluation was offered to all resident providers who held a 
weekly continuity clinic at the study site (n=59).  This session was taught by the same person 
(TMB) during the regularly scheduled pre-clinic conference from 1/12/09-1/16/09.  Resident 
providers who were not present for these sessions were provided the educational materials and 
instructed to review them independently (n=13). 
Data Collection and Variables 
The EMR for each  encounter was reviewed manually by a research assistant who 
collected the following information from the visit: patient age, sex, self-reported race, medical 
history/co-morbid conditions, family history of CVD [defined as one or more of the following: 
early myocardial infarction (≤55 years for men, ≤65 years for women), cerebrovascular accident, 
CVD, HTN, dyslipidemia], presence of hypertensive symptoms (one or more noted: headache, 
nausea, vomiting, shortness of breath/dyspnea, chest pain, palpitations), anthropometrics, and 
BP.  Body mass index (BMI) and BMI z-score were calculated according to the 2000 Centers for 
Disease Control and Prevention Growth Charts36.  Children were categorized as being 
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overweight/obese if their BMI was ≥85th percentile or ≥25kg/m2 if they were 20 years of age or 
older.   
The intake BPs were indexed to the 90th percentile by taking the measured BP and 
dividing it by the 90th percentile BP for each individual’s age/sex/height percentile.  A systolic or 
diastolic BP index ≥1 indicates an elevated BP.  In the instance that BP was repeated in triage 
(n=93), the average of the two BPs was indexed to the 90th percentile.  In addition, each child’s 
systolic and diastolic BP were categorized as at/above vs. below 120 mmHg and 80 mmHg, 
respectively.   
The outcome variable of the study was recognized elevated BP, defined as recognized if 
any of the following were documented in the EMR for each encounter: (a) provider repeated BP 
by manual auscultation; (b) provider assessment included abnormal BP, elevated BP or HTN; (c) 
provider plan included repeat BP or an evaluation for elevated BP.   
Data Analyses 
The overall prevalence of recognition during the intervention period was determined 
and compared to the prevalence in the pre-intervention time period by chi squared analysis.  
Elevated BP during patient encounters were dichotomized as recognized vs. not, and patient, 
clinic and provider characteristics were compared between the two groups using student’s t-test 
for continuous variables and chi squared analyses for categorical variables. To more directly 
model the prevalence of recognition, univariate log-binomial regression was used to obtain the 
prevalence ratios of recognition by each characteristic.  Multivariable log-binomial regression, 
adjusting for educational session attendance, was conducted to determine the impact of 
educational sessions on recognition.  In addition, the prevalence of recognition by various 
characteristics was compared between the pre-intervention and intervention period using chi 
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squared analyses. Analyses were conducted using Stata 11.0 (StataCorp, College Station, TX).  A 
p-value of <0.05 was considered to be statistically significant. 
Results 
During the six month intervention period, there were 1305 encounters with elevated BP 
(Figure 1) out of 5919 total encounters of 3285 unique patients.  Overall, 42% (556/1305) of 
encounters with an elevated BP were recognized during the intervention period compared to 
12.5% (100/803) recognized during the pre-intervention period (p<0.001).  The prevalence of 
recognition remained stable throughout the six month intervention period (Figure 2).  In the 
intervention period, children who were older, non-African American, male, overweight/obese, 
or with a family history of CVD, a personal history of co-morbid condition(s) or a systolic BP≥120 
mmHg were more likely to have their elevated BP recognized (Table 8).  Complaints of 
hypertensive symptoms (defined in Table 8 subscript c), lack of a significant medical history, 
diastolic BP≥ 80 mmHg, provider type, and educational session attendance were not associated 
with recognition.  During the intervention period, elevated BP was less likely to be recognized 
during an acute care visit than during a scheduled appointment. 
Overall, recognition significantly increased from the pre-intervention to the intervention 
period for each patient, clinic and provider characteristic (Table 9).  Within each period, there 
was no difference in recognition by provider type.  Forty-seven of the 59 resident providers 
attended the educational session; recognition was no different when stratified by educational 
session attendance (Table 9).    
The prevalence ratio (PR) of provider recognition was 2.6-3.7 times greater for each 
month in the intervention period compared to the pre-intervention period overall (Table 10); 
this difference persisted after adjusting for educational session attendance (p<0.001).  In 
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addition, compared to scheduled encounters, acute care visit encounters were associated with 
significantly decreased recognition (Table 10).  As observed pre- intervention, a systolic BP ≥120 
mmHg was associated with significantly greater recognition (PR 1.3, 95% confidence interval (CI) 
1.2, 1.5; p<0.001); however, the PR was not as large as observed during the pre-intervention 
period (PR 2.4, 95% CI 1.4, 3.9; p=0.001) (Figure 3).  Also, elevated BP encounters for children 
with increased CV risk (presence of overweight/obesity, higher BMI z-score, family history of 
CVD) or with a known co-morbidity were associated with greater provider recognition; however, 
as with systolic BP, the PRs were lower in the intervention period (Figure 3).   
Several variables not associated with elevated BP recognition pre-intervention were 
significantly associated with increased recognition in the intervention period: older age, male 
sex, and non-AA race (Figure 3).  Absence of significant medical history was no longer predictive 
of recognition in the intervention period (pre-intervention PR 0.4, 95% CI 0.2, 0.7, p=0.002; 
intervention PR 1.1, 95% CI 0.8, 1.5, p=0.7).   
Several sensitivity analyses were conducted.  In this study, we used the average of all 
intake BPs to determine if a child’s BP was elevated.  Because providers may disregard the first 
measurement and instead use the most recent measurement in their assessment, we examined 
recognition prevalence using only the most recent intake BP.  Of the 93 encounters in which a 
BP was repeated prior to the provider encounter, 17 (18%) BPs were normal on repeat.  Re-
categorizing these BPs as “recognized” and excluding the five encounters with repeat BPs 
<120/80 and no height measurement in the EMR, the rate of recognition increased slightly to 
44% (573/1300).   
The pre-intervention period did not include acute care encounters.   To determine how 
inclusion of these encounters in the intervention period may have influenced our results, we 
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calculated the prevalence of recognition after excluding acute care encounters.  In this analysis, 
the prevalence of recognition increased to 49% (p=0.003, compared to pre-intervention period). 
Discussion 
In this study of clinic encounters of patients 3-21 years of age without prior history of 
HTN in an urban, academic primary care center, we demonstrated that implementation of an 
automated EMR alert significantly increased provider recognition of elevated BP.  The 
educational session that focused on proper BP measurement and elevated BP recognition and 
evaluation did not impact recognition as demonstrated in adjusted and stratified analyses.  
Recognition increased soon after implementation and was sustained throughout the six month 
study period; there was no evidence of “alert fatigue”, i.e. no decline in recognition after an 
initial peak.   Many of the same characteristics associated with recognition in the pre-
intervention period22 were also associated in the intervention period; however, the magnitude 
of these associations significantly decreased.  Overall, these results support the hypothesis that 
the complex steps required to recognize elevated BP in children hinder recognition.  Electronic 
alerts can replace the cumbersome process in which providers manually compare a patient’s BP 
to the age/sex/height percentile BP tables.   
As shown previously, patient characteristics that increase the risk of high BP were 
associated with greater recognition of elevated BP22.  Children with a greater BMI z-score or 
categorized as overweight/obese, those with a family history of CVD, and those with co-morbid 
conditions such as diabetes or kidney disease were more likely to have their elevated BP 
recognized than were children without these characteristics.  Interestingly, recognition was less 
influenced by the presence of these CV risk factors in the intervention period. While many 
remained positively associated with recognition, the magnitude was significantly decreased.  In 
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fact, having no significant medical history neither increased nor decreased the probability of 
recognition, whereas previously this patient characteristic was associated with a 60% decrease 
in recognition. Similarly, healthy weight children with elevated BP were much less likely to have 
their elevated BP recognized than overweight/obese children in the pre-intervention period.  
After implementation of the EMR alert, the PR of recognition increased from 0.4 to 0.8, 
providing evidence that these children were less likely to be missed.  These findings imply that 
the alert may have helped bridge the gap between those with and without obvious CV risk 
factors, allowing for enhanced recognition of elevated BP in those who would not otherwise 
appear to be at risk.   
During the intervention period, elevated BP recognition was less dependent on 
extremely elevated BP.  While systolic BP at or above the commonly recognized threshold of 120 
mmHg was 1.3 times more likely to be recognized than elevations below 120 mmHg, this 
“advantage” was less prominent than in the pre-intervention period when such a BP extreme 
was associated with a 2.4 times increase in recognition.      
Several patient characteristics were associated with elevated BP recognition in the 
intervention period that were not associated pre-intervention.  Males and AA children were 
more likely to have their elevated BP recognized than females and non-AA, respectively. Greater 
recognition of HTN in these patient groups has been shown in adults37. The racial differences in 
recognition may reflect greater physician awareness of CV risk in minority racial groups as 
suggested by Banerjee et al.37  The lack of an association prior to alert implementation may have 
been due to the poor rate of recognition overall or reduced statistical power because there 
were fewer clinical encounters with elevated BP in the pre-intervention period than the 
intervention period.    
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Another notable finding is that the increase in recognition was sustained over the 
course of the six months study period.  One of the main concerns providers have with 
computerized alerts is that they will become desensitized to alerts over time and less likely to 
notice and/or respond to them38 or more likely to override built-in hard stops39, 40.  Results from 
our study dispel this concern.   
While increasing provider awareness and education are essential elements of increasing 
recognition of elevated BP, this study suggests that simplification of a non-intuitive process is 
critical to achieving improved recognition in a pediatric population.  A systematic review of 
studies evaluating the impact of provider education on clinical practice in the management of 
HTN found only one randomized controlled trial utilizing formal CME training that resulted in a 
decrease in systolic BP but no long term change in diastolic BP, BMI, or pattern of BP medication 
use.   Other randomized controlled trials found no change in BP control with formal CME or 
educational materials41 .   
While recognition of elevated BP did increase, over 55% of encounters with elevated BP 
in the intervention period remaining unrecognized.  With the increased prevalence of HTN and 
other CV risk factors and the mounting evidence that the origins of CVD are in childhood, further 
improvements in recognition are needed.  While many of these children likely do not have HTN, 
as that is determined by the sustained elevation of BP over time, having intermittently elevated 
BP increases one’s risk for the ultimate development of HTN.   A child with a BP >95th percentile 
that normalizes on repeat measurement has a greater chance of developing HTN (1.4% 
incidence per year) than a child with normal BP (0.3% per year) or one with confirmed pre-
hypertension (1.1% per year).  Having a BP >95th percentile that decreases only to the pre-
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hypertensive range increases one’s risk for developing HTN to an even greater degree (6.6% per 
year)42.  
Our study has limitations.  First, recognition of elevated BP was defined by information 
obtained from completed provider clinic notes.  It is possible that not all recognized elevations 
were documented in the EMR.  In addition, 51 encounters did not have a transcribed clinic note 
to review, which may have influenced our results.  Second, this study was unable to capture 
how many times a BP was not obtained.   It is routine practice in this clinic to measure BP during 
all health care encounters, but we are unable to confirm whether or not this occurred.   Finally, 
this study is a pre-post evaluation, not a randomized trial.  Such a trial would likely be a cluster 
randomized trial.  Given the nature of the intervention, which is a system change, such a trial 
would be logistically difficult and likely impractical because of cost and feasibility considerations. 
Finally, the intervention period included data from both scheduled clinic and acute care 
encounters, as opposed to the pre-intervention period, in which data collection focused solely 
on scheduled clinic encounters.  Still, we conducted a sensitivity analysis that excluded acute 
care encounters in the intervention period.  This analysis revealed an increase in recognition 
prevalence from 42% to 49% and suggests that the intervention may enhance recognition to a 
greater degree during regular scheduled visits.    
Our study also has several strengths.  To our knowledge, it is the first study that directly 
compares the impact of an electronic alert on recognition of elevated BP in a pediatric primary 
care population.  Second, the study was conducted in a large, urban, academic center that 
serves a high risk community.  Third, it is likely that all encounters with elevated BP were 
detected.   There was no reliance on chart screening to identify instances of elevated BP.   
Rather, monthly reports were generated listing each encounter where an alert occurred.  
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Fourth, recognition was based on thorough chart review of clinic notes and did not rely on 
billing codes or administrative data. 
Conclusion 
 In conclusion, real time EMR alerts can substantially increase provider recognition of 
elevated BP in children and hold considerable promise as a means to improve adherence to 
practice guidelines.  Still, under-recognition of elevated BP in children persists.  Additional 




Figure 1: Flow Diagram of Included Encounters and Provider Recognition in the Intervention 
Period 
 





Figure 2: Percent of Elevated Blood Pressure Measurements Recognized by Providers during 
the Pre-Intervention and Intervention Periods  
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Figure 3: Prevalence Ratios of Elevated Blood Pressure Recognition by Various Characteristics 
during the Pre-Intervention and Intervention Periods 
 
AA=African American; BMI= Body Mass Index; CVD=cardiovascular disease 
aBMI z-score is the standard deviation score determined using Centers for Disease Control 
growth charts. 
bHealthy Weight defined as a BMI<85th percentile and <25kg/m2 if ≥20 years of age; compared 
to being overweight/obese which is defines as a BMI≥85th percentile or ≥25/m2 if ≥20 years of 
age 
cFamily history of CVD defined as any of the following: early myocardial infarction, 
cerebrovascular accident, cardiovascular disease, high cholesterol, hypertension 
dCo-Morbid conditions include past medical history of any of the following: obesity, metabolic 




Table 8. Characteristics of Encounters with Recognized Elevated Blood Pressure, Pre-Intervention and Intervention Periods 
 
Pre-Intervention Intervention 
  Blood Pressure Elevation   Blood Pressure Elevation  





































or n  
Age (yrs) 12.6  5.1 12.2  4.8 12.7  5.1 0.36 12.9  5.9 13.3  5.7 12.6  5.9 0.02 
African American 93.0%  747 91.0%  91 93.3%  656 0.40 93.2%  1216 91.6%  509 94.4%  707 0.05 
Male Sex 43.6%  350 38.0%  38 44.4%  312 0.24 41.2%  538 45.9%  255 37.8%  283 0.004 




17.5 30.4  
N=96 
44 23.7  
N=661 
8.2 0.14 25.4 
N=824 
8.6 25.9  
N=405 





51.3%  388 75.0%  72 47.8%  316 <0.001 55.1%  
 
454 60.5% 245 49.9%  209 0.003 
Acute Care Visit N/A       34.6%  
N=1265 
437 24.5%  132 42.0%  305 <0.001 




48 11.1%  
N=99 
11 5.3%  
N=702 
37 0.04 24.1%  
N=435 
105 31.0%  
N=197 






12.2%  98 11.1%  11 12.4%  87 0.87 18.6%  243 18.9%  105 18.4%  138 0.83 
Presence of co-
morbid conditionsd 
20.4%  164 40.0%  40 17.6% 124 <0.001 22.6%  295 31.1%  173 16.3%  122 <0.001 
No Significant 
Medical History 
26.7%  214 13.0%  13 28.6%  201 0.001 96.2%  1255 96.4%  536 96.0%  719 0.77 
SBPe ≥ 120 mmHg 67.5%  542 83.0%  83 65.3%  459 <0.001 64.0%  835 70.3%  391 59.3%  444 <0.001 
DBPe ≥80 mmHg 65.8%  46 9.1%  9 5.3%  37 0.16 8.0%  104 9.0%  50 7.2%  54 0.26 
SBP indexf 1.02  
N=719 
0.06 1.07  
N=93 
0.08 1.02  
N=626 
0.06 <0.001 1.01  
N=712 
0.07 1.02  
N=353 





DBP indexf 0.84  
N=714 
0.14 0.97  
N=92 
0.14 0.83  
N=622 
0.14 0.02 0.89  
N=712 
0.13 0.88  
N=353 
0.13 0.89  
N=359 
0.12 0.78 






N/A       60.1%  499 58.8%  213 61.1%  286 0.52 
aBody Mass Index (BMI) ≥85th percentile or BMI≥25 kg/m2 if age≥20 
bFamily history of cardiovascular (CV) disease includes any of the following: early myocardial infarction, cerebrovascular accident, cardiovascular disease, high 
cholesterol, hypertension 
cDefined as the presence of any of the following in the encounter note: headache, nausea, vomiting, shortness of breath, chest pain, palpitations 
dCo-morbid conditions include past medical history of any of the following: obesity, metabolic syndrome, insulin resistance, diabetes mellitus, kidney disease or 
prematurity 
eSystolic Blood Pressure, Diastolic Blood Pressure 
fThe systolic/diastolic blood pressure index (SBP index/DBP index) is defined as the measured systolic or diastolic blood pressure (BP) divided by the 




Table 9. Prevalence of Recognized Elevated Blood Pressure in the Pre-Intervention and Intervention Periods Stratified by Patient, Clinic and 
Provider Characteristics 






 Number of 
encounters with 
elevated BP 
% recognized  
 N % N p-valuea N % N p-valuea p-valueb 
Patient Demographics          
Age           
   ≥ 12 years 452 12.0%  54 0.67  753 45.4%  342 0.02 <0.001 
   < 12 years 351 13.1%  46   552 38.8%  214  <0.001 
Sex           
   Male 350 10.9%  38 0.24  538 47.4%  255 0.004 <0.001 
   Female 453 13.7%  62   767 39.2%  301  <0.001 
Race           
   African American 747 12.2%  91 0.40  1216 41.9% 509 0.05 <0.001 
   Non-African American 56 16.1% 9   89 52.8%  47  <0.001 
Medical History           
Family History of 
Cardiovascular Diseasec 
          
   Yes 48 22.9%  11 0.04  105 58.1%  61 0.003 <0.001 
   No 753 11.7%  88   330 41.2%  136  <0.001 
Presence of Co—Morbid 
Conditionsd 
          
   Yes 164 24.4%  40 <0.001  295 58.6%  173 <0.001 <0.001 
   No 639 9.4% 60   1010 37.9%  383  <0.001 
Past Medical History           
   Any 589 14.8%  87 0.001  50 40.0%  20 0.77 <0.001 
   None 
 
214 6.1% 13   1255 42.7%  536  <0.001 
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Clinical Measurements           
Adiposity           
   Overweight/Obesee 388 18.6% 72 <0.001  454 54.0% 245 0.003 <0.001 
   Healthy Weightf 369 6.5% 24   370 43.2% 160  <0.001 
Blood Pressure           
   SBP≥120 mmHg 542 15.3% 83 <0.001  835 46.8% 391 <0.001 <0.001 
   SBP<120 mmHg 261 6.5% 17   470 35.1% 165  <0.001 
   DBP≥80 mmHg 46 19.6% 9 0.16  104 48.1% 50 0.26 0.001 
   DBP<80 mmHg 752 12.0% 90   1201 42.1% 506  <0.001 
Provider Characteristics           
Provider Type           
Nurse Practitioner 173 9.3% 16 0.28  247 42.9% 106 0.40 <0.001 
Fellow/Attending 78 10.3% 8   228 38.6% 88  <0.001 
Resident 549 13.7% 75   830 43.6% 362  <0.001 
Educational Session 
Attendance 
          
Resident attendedg N/A     499 42.7% 213 0.52  
Resident did not attend  N/A     331 45.0% 149   
Clinic Characteristic           
Clinic Type           
Resident Clinic 549 13.7% 75 0.11  830 43.6% 362 0.35 <0.001 
Non-resident clinic 251 9.6%  24   475 40.8% 194  <0.001 
aComparing prevalence of recognition by each characteristic within each time period (pre-intervention or intervention period); bComparing prevalence of 
recognition pre-intervention to intervention period, by individual stratum of characteristics; cFamily history of any of the following: early myocardial infarction, 
cerebrovascular accident, cardiovascular disease, high cholesterol, hypertension; dCo-morbid conditions include past medical history of any of the following: 
obesity, metabolic syndrome, insulin resistance, diabetes mellitus, kidney disease or prematurity; eBody Mass Index (BMI) ≥85th percentile or BMI≥25 kg/m2 if 





Table 10.  Prevalence Ratio (PR) of Recognized Elevated Blood Pressure during the Pre-

















Study Period        
- Pre-Intervention ref    ref   
- Intervention        
o Month 1 2.6 1.8, 3.9 <0.001  2.6 1.8, 3.9 <0.001 
o Month 2 3.6 2.9, 4.5 <0.001  3.6 2.8, 4.5 <0.001 
o Month 3 3.7 3.0, 4.7 <0.001  3.7 2.9, 4.7 <0.001 
o Month 4 3.0 2.4, 3.8 <0.001  3.0 2.3, 3.8 <0.001 
o Month 5 3.4 2.7, 4.3 <0.001  3.4 2.7, 4.3 <0.001 
o Month 6 3.6 2.9, 4.6 <0.001  3.6 2.8, 4.5 <0.001 








Background/Objective: Left ventricular hypertrophy is highly prevalent at initial diagnosis of 
hypertension in children, however degree of blood pressure elevation does not predict its 
presence.  We hypothesized that obesity and obesity-related risk factors are associated with left 
ventricular mass index in hypertensive children, and that the association between adiposity and 
left ventricular mass index is mediated by blood pressure dependent and independent 
pathways.   
Methods/Results: We observed 49 treated hypertensive children for one year.  At baseline, 51% 
were overweight/obese and 41% had left ventricular hypertrophy.  Those with left ventricular 
hypertrophy had greater body mass index z-score but did not have greater clinic or 24-hour 
ambulatory blood pressures than those without left ventricular hypertrophy.  Over time, 
measures of adiposity and prevalence of cardiovascular risk factors increased while blood 
pressure was unchanged.  Children who were obese at both study visits experienced the 
greatest increase in left ventricular mass index over time: mean change was 6.4 g/m2.7 (95% 
confidence interval 2.4, 10.5) among those overweight/obese at each visit, vs. 0.95 g/m2.7 (95% 
confidence interval -3.2, 5.1) among those of healthy weight at each visit (p=0.056; Figure 1).  
Overweight/obese children with and without left ventricular hypertrophy at baseline 
demonstrated a larger increase in left ventricular mass index compared to healthy weight 
children.  Healthy weight children with left ventricular hypertrophy were the only ones with 
decreased left ventricular mass index over time. Body mass index z-score at baseline was 
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associated with change in left ventricular mass index (β 4.08, 95% confidence interval 1.54, 6.61, 
p=0.002) after adjusting for age, sex, race, and left ventricular mass index at baseline.  After 
adjustment for each postulated mediating pathways between body mass index z-score and left 
ventricular mass index in separate analyses, only pulse pressure and serum aldosterone 
appeared to partially mediate this relationship.   
Conclusions: Hypertensive children demonstrate not only a high prevalence of co-morbid 
cardiovascular risk factors at baseline, but an increase in both their prevalence and severity over 
time.   Of these, body mass index z-score was the greatest risk factor for left ventricular 
hypertrophy and increasing left ventricular mass index over time.  These findings support the 
overwhelming public health concern regarding the obesity epidemic and suggest that greater 
emphasis on overweight/obesity prevention and treatment should be made among 





The prevalence of cardiovascular disease (CVD) risk factors in children continues to rise.  
In the United States, it is estimated that 4.5% of children have hypertension3, almost a third are 
overweight or obese7, and nearly 20% have dyslipidemia43.  Overall, at least 24.5 million of the 
74.2 million children in the United States4 have one or more of these CVD risk factors.  A recent 
systematic review and meta-analysis suggests that obesity may account for much of this 
increased risk44.  In fact, while increased sodium intake, decreased potassium intake and 
suboptimal diet overall are known to raise blood pressure (BP), the striking increase in the 
prevalence of hypertension over the last several decades has been attributed to the coincident 
epidemic rise in obesity6.   
While children with obesity, hypertension and dyslipidemia are typically asymptomatic, 
they manifest alterations to their cardiovascular system previously thought only to occur in 
adulthood.  Left ventricular hypertrophy (LVH), a pathological remodeling of the heart 
associated with arrhythmias, heart failure, myocardial infarction and death in adults3, 9, is a 
common manifestation of early CVD in children3.  Hypertension has been considered the main 
cause of LVH, presumably as a response to increased left ventricular afterload.  As such, 
echocardiography is recommended for all hypertensive children to investigate for this form of 
target-organ damage, the presence of which necessitates initiation or escalation of 
antihypertensive pharmacological therapy.   
Among children with hypertension, LVH is common, with up to 41% having LVH at initial 
diagnosis3, 9.  Interestingly, neither BP measured in clinic nor in the ambulatory/home setting is 
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consistently associated with LVH in hypertensive children9, 45.   Further, LVH can occur in 
normotensive children46, 47, is more prevalent among children with the metabolic syndrome than 
without48, and is independently associated with obesity9, 44, 47, 49.  These findings suggest that 
mechanisms independent of BP may also be responsible for the development of LVH among 
hypertensive children.  Identifying these risk factors will aid risk stratification and targeted 
treatment efforts. 
We investigated the association between adiposity as assessed by body mass index 
(BMI) z-score and left ventricular mass index (LVMI) among hypertensive children.  We 
hypothesized that obesity and obesity-related risk factors are associated with LVMI in 
hypertensive children.  We also hypothesized that adiposity leads to increased LVMI via several 
pathways: BP dependent pathways, mediated by elevated BP itself and by hormonal regulators 
of BP; and BP independent pathways, mediated by metabolic dysregulation, increased 
intravascular volume and inflammation. 
Methods 
Study Design: 
We conducted a prospective, observational study of hypertensive children referred for 
care at the pediatric nephrology clinic at Johns Hopkins University.  Hypertensive children 3-22 
years who either had a systolic or diastolic BP ≥95th percentile for their age/sex/height3 or who 
were on antihypertensive medication for the treatment of hypertension at the time of their 
clinic visit were eligible.  Children with a history of congenital heart disease, cancer or chronic 
kidney disease stage 2 or greater were ineligible.  The Johns Hopkins University School of 
Medicine Institutional Review Board approved this study. 
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Data Collection and Variables:  
All enrolled children provided informed consent or assent when <18 years.  Each 
participant underwent a standardized assessment at baseline and 12-month follow-up in the 
Pediatric Clinical Research Unit.  At each assessment, demographic and clinical information were 
collected.  Children provided a 3-day diet history that was reviewed for accuracy and enhanced 
recall regarding additional pertinent details (e.g. condiments, serving sizes) at each visit by a 
registered research dietician.   
 All children underwent anthropometric measurements including height, measured to 
nearest 0.1 cm using a wall mounted stadiometer and weight, measured to the nearest 0.1 kg 
using a calibrated balance scale.  Waist circumference measurements were taken 1 cm above 
the patients’ navel on exhale, using a Gulick tape measure which applies known tension. 
Standard hip circumference measurement was taken at the widest girth around the hip and 
buttocks. All measurements were taken in triplicate according to research protocol and the 
mean recorded to the nearest 0.1 cm.   
Each participant’s Clinic Blood Pressure (CBP) was measured by manual auscultation 
after 5 minutes of rest in the right arm with a calibrated aneroid sphygmomanometer according 
to standardized methods50.  Mid-arm circumference in cm was used to select the appropriate 
cuff size. Three seated measurements were taken 30 seconds apart and then averaged together 
for one composite measurement for the visit.  Individuals responsible for CBP measurement 
undergo training and are required to pass certification evaluations yearly.   
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All children also underwent 24-hour oscillometric ambulatory BP Monitoring (ABPM) 
according to research protocol51 with BP measurements obtained every 20 minutes over a 24-
hour period of time (Spacelabs 90201).  As above, their mid-arm circumference was used to 
select an appropriate cuff size.  Awake and Sleep cutoffs were determined by diary.  Systolic and 
diastolic BP dip was calculated as ([mean wake BP-mean sleep BP]/mean wake BP x 100).  As BP 
norms for children vary based on age/sex/height, to compare BP elevations between children 
each child’s systolic and diastolic BP (clinic and 24-hr ABPM BPs) was divided by his/her 
age/sex/height specific 95th percentile BP3, 51.  This calculation provides a 95th percentile BP 
index, with values ≥1 indicating measurements ≥95th percentile (i.e. in the hypertensive range).    
Clinic and 24-hour ABPM pulse pressure were also calculated (systolic BP – diastolic BP in 
mmHg).   
In addition, as part of the cohort protocol, all children underwent a complete 
echocardiographic examination.  Images from the standardized two-dimensional guided M-
mode assessment for left ventricular mass (LVM) were digitally recorded.  Three measurements 
were taken for each subject and averaged by a single study cardiologist (KWH).  LVM was 
calculated based on diastolic measurements of the left ventricular dimension, intraventricular 
septum and left ventricular posterior wall using a validated equation as recommended by the 
American Society of Echocardiography52, 53.  LVMI was then calculated by dividing the LVM by 
the participant’s height in meters2.7; an individual was determined to have LVH if his/her LVMI 
was ≥95th percentile for their age and sex54.  
Laboratory Assessments:  All children had a random blood sample drawn at both their baseline 
and 12-month assessments.  Serum aldosterone (ng/dL) and plasma renin activity (ng/mL/h) 
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were measured at Quest Diagnostics using liquid chromatography tandem mass spectrometry 
(LC/MS/MS), with an analytical sensitivity of 1.0 ng/dL and 0.03 ng/mL/h respectively.   High 
sensitivity C-reactive protein (hsCRP; mg/dL) was determined using highly-sensitive 
immunonoturbidimetry and hemoglobin A1c (%) was measured by high performance liquid 
chromatography.  Serum uric acid concentration (mg/dL) was determined by enzymatic 
spectrophotometry.  Additional laboratory assessments included 25-hydroxyvitamin D (ng/mL); 
lipids (total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides; all 
mg/dL); lipoprotein (a) (nmol/L) and pro-B natriuretic peptide (pg/ml).  Children provided a 24-
hour urine collection; sodium excretion in mg was calculated by multiplying the total urine 
volume by the measured sodium concentration.    
Demographic and Clinical Characteristics: 
Children were categorized as African American (AA) or non-AA based on self-report.  
Body mass index (BMI) was calculated as kg/m2 and age-sex specific BMI percentiles and z-
scores were determined55, 56.   Children were defined as overweight/obese if their BMI 
percentile was ≥85th percentile57.  Age/Sex/Race-adjusted waist-circumference percentile norms 
were used to categorize children as ≥90th percentile58 or below.  The waist-hip ratio was 
calculated as the waist circumference divided by the hip circumference (both in cm).  
Metabolic syndrome was defined as having ≥3 of the following: systolic or diastolic BP 
≥90th percentile; BMI >97th percentile; triglycerides >110 mg/dL; HDL <40 mg/dL; waist 




Demographic and clinical variables were compared between children with and without 
LVH using student’s t-tests with unequal variances for continuous variables that were normally 
distributed, Wilcoxon Rank Sum for continuous variables not normally distributed and Fisher’s 
exact tests for categorical variables.  As several variables of interest had missing values, felt to 
be missing at random, we conducted multiple imputation utilizing all available information on 
related covariates.  This imputed dataset was used to conduct the analyses detailed below.  
There were no missing data for LVMI or BMI and BMI z-score.  Analyses using the dataset with 
missing data were compared with those conducted using the imputed dataset to assess the 
appropriateness of imputation.   
To assess for longitudinal associations between variables and LVMI over time, delta 
variables were calculated (12-month follow-up measurement - baseline measurement) for LVMI 
and variables of interest.  Because the distribution of delta LVMI measurements did not deviate 
significantly from a normal distribution, we used linear regression to quantify the association 
between change in LVMI and characteristics at baseline and change over time, adjusting for age, 
sex, and race.   
To investigate the association between adiposity and LVMI over time, we conducted 
linear regression analysis with baseline BMI z-score as the independent variable and delta LVMI 
as the dependent variable.  These analyses were initially adjusted for age, race, and sex, and 
then further adjusted for LVMI at baseline in a second model to serve as the base model for 
subsequent analyses described below.  
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We chose baseline BMI z-score as the independent variable instead of other markers of 
adiposity because this was felt to best represent degree of adiposity among children.  Further, 
because BMI and waist circumference values defining overweight and obesity in children change 
with increasing age58, 60 using z-scores allow us to compare values between children of varying 
ages.    
To investigate the relative contribution of the hypothesized mediating pathways 
between adiposity and LVMI, and to determine if adiposity, as ascertained by BMI z-score, was 
independently associated with LVMI, we conducted several additional linear regression 
analyses.  These separate analyses started with the base model as the foundation and further 
adjusted for the variables hypothesized to mediate the relationship between adiposity and 
LVMI.   In these analyses, we expected to see an attenuation of the association between BMI z-
score and LVMI for variables that mediate the relationship between adiposity and LVMI.  For risk 
factors that do not mediate this association, we expected unchanged or similar point estimates 
and p-values to describe the association between BMI z-score and LVMI despite the addition of 
the variable to the model.   
A two-sided P value <0.05 was considered statistically significant.  Statistical analyses 
were conducted using STATA 11.2 software (StataCorp LP, College Station, TX).  Study data were 
collected and managed using REDCap (Research Electronic Data Capture) electronic data 





Forty-nine children 3-19 years of age completed both baseline and 12-month 
assessments out of 53 enrolled (92% retention; 2 disenrolled, 2 lost to follow-up).  Forty-one 
percent had LVH at baseline.  The average length of time between the follow-up assessments 
was 12.8 months.  Over the course of follow-up, the mean (standard deviation (SD)) change in 
LVMI was 2.89 g/m2.7 (8.4 g/m2.7).  Of the measures of adiposity, the mean change in BMI was 
1.6 kg/m2 (2.1 kg/m2), mean change in BMI z-score was 0.11 (0.32), and the mean change in 
waist circumference was 4.6 cm (5.9 cm).  The percentage of children classified as 
overweight/obese was 51% at baseline and 57.1% at follow-up (p=0.69).  BP changed to a 
minimal degree over the course of the study: the average change in clinic SBP was -0.14mmHg 
(12.5), average change in clinic SBP index was -0.02 (0.09), average change in awake SBP was 
0.52mmHg (9.5) and average change in awake SBP index was -0.001 (0.07).  Forty-four children 
were prescribed antihypertensive medications at baseline, with 43 prescribed anti-hypertensive 
medications at follow-up.  The majority of children reported participating in at least 30 minutes 
of physical activity three times a week: 41 at baseline and 44 at follow up.  The prevalence of 
LVH at follow-up was 53.1% (vs. 40.8% at baseline; p=0.31). 
Baseline Characteristics 
As one would expect, children with LVH had greater LVMI compared to those without 
LVH (Table 11a).  There were no age, sex or race differences between the two groups, but there 
was a greater proportion of children with a positive OSA screen (defined when >30% positive 
responses on validated questionnaire62, 63) among those with LVH.  Children with LVH also had a 
greater BMI z-score, but did not have evidence of increased visceral adiposity as represented by 
waist circumference or waist-hip ratio when compared to children without LVH. Children with 
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LVH also had a higher serum uric acid level, a lower serum lipoprotein (a) level and a greater 
pro-B natriuretic peptide level than those without LVH.  High sensitivity CRP and urinary sodium 
excretion values were non-significantly higher in those with LVH (1.1 mg/dL vs. 0.40 mg/dL for 
hsCRP; 4.2 grams vs. 3.5 grams for urinary sodium excretion).   
There was no difference in BP between those with and without LVH when measured at 
rest by manual auscultation or by 24-hour ABPM (Table 11b).  The median plasma renin activity 
was also no different between the groups.  Serum aldosterone, however, was higher amongst 
children with LVH who were prescribed an Angiotensin Converting Enzyme inhibitor (ACEi) or 
angiotensin II receptor blocker (ARB) when compared to those without LVH who were also 
prescribed one of those medications.   
Longitudinal Associations 
In linear regression analyses that separately assessed each independent variable, age, 
waist circumference at baseline, and change in hemoglobin A1c were associated with change in 
LVMI over time while adjusting for age, sex and race (Table 12).  Children who were overweight 
or obese at both study visits experienced the greatest increase in LVMI over time: mean change 
in LVMI was 6.4 g/m2.7 (95% CI 2.4, 10.5) among those overweight or obese at each visit, vs. 0.95 
g/m2.7 (95%CI -3.2, 5.1) among children who were of healthy weight at each visit (p=0.056; 
Figure 4).  In addition, when stratified by weight status (healthy weight vs. overweight/obese) 
and LVH status at baseline, overweight/obese children with and without LVH demonstrated a 
larger increase in LVMI compared to healthy weight children.  In fact, healthy weight children 




Baseline adjusted analyses revealed a significant relationship between BMI z-score at 
baseline and change in LVMI over time (β 4.08, 95% CI 1.54, 6.61, p=0.002; Table 13).  
Sequential adjustment for BP, markers of metabolic dysregulation, and markers of inflammation 
(hsCRP and 25-hydroxy vitamin D) revealed essentially no change in the point estimate or p-
values between BMI z-score and change in LVMI.  The models adjusting for serum aldosterone 
with ACEi/ARB use and pulse pressure resulted in a decrease in both the point estimate and p-
value, suggesting partial mediation.   
Discussion 
In this year-long observational study of hypertensive children, we demonstrated a high 
burden of co-morbid CVD risk factors at baseline, and an increase in both their prevalence and 
severity over time.   Most striking was the presence and substantial degree of overweight and 
obesity; over 50% of the cohort was both overweight and obese, much more than the 
prevalence in the United States population overall (32%7).  These CVD risk factors, specifically 
uric acid, measures of adiposity, lipids, hemoglobin A1c, and hsCRP, along with target organ 
damage felt to be secondary to hypertension itself, increased/worsened over time despite 
relatively good BP control as evidenced by the mean BP index being <1 at baseline and 
decreasing over time.  Over time, adiposity, not BP, was demonstrated as the greatest risk factor 
for LVH and increasing LVMI among these hypertensive children.  These findings support the 
overwhelming public health concern regarding the obesity epidemic and suggest that greater 
efforts are needed to prevent and treat overweight/obesity in hypertensive children.   
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While several other studies in children have described the impact of CVD risk factors on 
target organ damage, ours is the first to report longitudinal data on a racially diverse population 
of hypertensive children without kidney disease.   Litwin et al. demonstrated that among 
European children with incident primary hypertension, successful treatment of hypertension 
was not independently associated with decrease in LVMI.  In fact, there was no difference in the 
prevalence of LVH between those children who “responded” to antihypertensive therapy and 
those who did not.  Instead, adiposity had the strongest association with LVMI over time, with 
decreasing waist circumference being the main predictor of decreasing LVMI. 
Adult studies also provide evidence that adiposity may be more important in 
determining LVM than BP.  Obese adults who lost weight after bariatric surgery also had 
concomitant reductions in BP, LVM and relative wall thickness.  Interestingly,  their BP reduction 
was not associated with decreased LVM or improved LV structure64.   
Normotensive children also provide evidence for the greater role of adiposity on LVM 
when compared to BP.  A dietary intervention trial of Finnish children followed yearly from 
seven months of age to adolescence revealed the strongest determinant of LVM to be an 
adolescent’s concurrent weight26.  While children in the intervention group enjoyed significant 
improvements in diet, lipids, BP and endothelial function, they did not experience significant 
changes in weight, LVM or LVH26, 27.  So, while improved diet quality was able to decrease BP 
among these normotensive children, lower BP did not impact LVM or the presence/absence of 
target organ damage in the form of LVH.   
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One of the indications for initiation or intensification of antihypertensive medication 
among hypertensive children is the presence of LVH.  Recommendations suggest aiming for a 
more aggressive BP treatment goal of <90th percentile when LVH is present3.  Given these 
recommendations, the pattern of change in LVMI among healthy weight children with and 
without LVH as demonstrated in Figure 5 is not surprising.  Particularly given the age related 
changes in LVMI over time, those children without LVH could be expected to have an increase in 
LVMI over time; and as long as this increase did not indicate the development of LVH, this could 
be considered a normal finding.  Children with LVH, however, would be expected to 
demonstrate a decrease in LVMI with successful pharmacological treatment, as the healthy 
weight children with LVH experienced.   
Conversely, the pattern of change in LVMI among children who were overweight/obese 
is concerning.  While also not unexpected that overweight/obese children without LVH could 
have an increase in LVMI, they demonstrated an increase that was 2.5 times higher than 
experienced by the healthy weight children without LVH.  Further, those overweight/obese 
children with LVH experienced almost as large of an increase as those without LVH, not the 
expected decrease over time.  
Perhaps the most striking finding in our study was the strong independent association 
between adiposity and change in LVMI over time that remained despite sequential adjustments 
for multiple mediating pathways.   The two variables that partially mediated this association, 
serum aldosterone and pulse pressure, are potentially modifiable risk factors for increasing 
LVMI.   The adipocyte is an endocrine organ that secretes neurohumoral factors that influence 
cardiac remodeling directly and contribute to intravascular volume expansion.  These factors 
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lead to increased, and possibly inappropriate, aldosterone secretion.  In the setting of excess 
sodium intake, this excess aldosterone excretion contributes to the target organ damage found 
in hypertensive individuals65, 66 and can cause increased intravascular volume.  The role of this 
neurohumoral pathway was also demonstrated in the bariatric surgery intervention study 
described earlier, where the authors concluded that the effect of weight loss on cardiac 
geometry was primarily mediated by the associated decrease in intravascular volume and 
reversal in hormonal abnormalities, not by a decrease in BP64.   
The strong association between BMI z-score and change in LVMI that remains despite 
adjusting for these factors suggests either an independent relationship between adiposity and 
LVMI or, more likely, an interaction of LVMI with many or all of these mediators.  Lending 
further support to this complex association are the multiple studies that describe different 
patterns of abnormal cardiac geometry among obese hypertensive compared to non-obese 
hypertensive individuals67.  Specifically, obese hypertensive individuals tend to exhibit eccentric 
hypertrophy 67, a geometric pattern associated with a  greater dietary sodium intake and larger 
intravascular volume68, 69.  Non-obese hypertensive individuals tend to have concentric 
hypertrophy, which is associated with more severely elevated BP in adults67, 68, 70.     
Our study has several limitations.  These include its relatively small sample size and 
observational design, which makes us unable to infer causality.  As children were recruited from 
a pediatric nephrology clinic, there may be a selection bias in that included children may have 
more severe hypertension than those who might have been recruited from a non-referral based 
office setting. In addition, the majority of the children were non-fasting at the time of their 
study visit.  As a result we were unable to include data regarding fasting insulin or glucose and 
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were unable to assess the homeostatic model assessment of insulin resistance (HOMA-IR).  We 
were therefore unable to fully ascertain the degree of metabolic dysfunction among the 
children in our cohort. 
Our study also has several strengths.  It provides data on a racially diverse population of 
hypertensive children at considerable CVD risk.  It’s longitudinal, prospective design allows us to 
minimize information bias and evaluate the relationship of various mediators of obesity and LVH 
on the change in LVMI over time.  The standardized echocardiograms read by a study 
cardiologist provide us with a robust estimate of the left ventricular size and prevalence of LVH.  
Our use of 24-hr ABPM provides a more precise assessment of BP than one set of clinic BP 
measurements71, 72.   
Perspectives: 
In sum, our study emphasizes the substantial contribution of obesity on CVD risk among 
hypertensive children and suggests that the presence of overweight/obesity should be elevated 
in importance when risk stratifying children with hypertension.  Despite providing standard of 
care guidance on weight loss and adherence to a heart healthy diet, the children in our study 
became more overweight/obese and demonstrated an increase in number and severity of CVD 
risk factors.  Successful treatment of these modifiable risk factors, known to be associated with 
increased CVD morbidity and mortality in adults, could potentially improve both pediatric and 
adult cardiovascular health by decreasing LVMI.  Enhanced preventive and therapeutic 
strategies targeting overweight and obesity in children holds significant promise as we work 
towards primordial and primary prevention of adult CVD.   
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Figure 5: Mean Change in Left Ventricular Mass Index by Weight and Left Ventricular 











Table 11a. Baseline Characteristics of 49 Hypertensive Children and Adolescents with and 




Overall  LVH 
(N=20) 






















LVMI (g/m2.7) 37.7  9.5  45.4  7.4  32.3  6.6  <0.0001 
Demographics           
Age (years) 13.8  3.9  14.3  4.1  13.4  3.8  0.48 
Male  29  59%  14  70%  15  52%  0.25 
African American  19  39%  2  25%  14  48%  0.14 
Medical History           
Positive OSA 
Screen 
10  21%  7  37%  3  10%  0.04 
Duration of HTN 
(mo) 
39.4  32.3  49.2  40.6  32.6  23.5  0.11 
Measures of 
Adiposity 
          
BMI (kg/m2) 25.3  7.6  27.8  9.0  23.5  6.0  0.07 
BMI z-score 1.2  0.98  1.5  0.7  0.9  1.1  0.03 
Overweight/obeseb 25  51%  13  65%  12  41%  0.15 
Waist 
circumference (cm) 
81.5  18.6  85.5  20.1  78.7  17.3  0.22 
Waist-hip ratio 0.88  0.08  0.88  0.08  0.88  0.08  0.73 
Inflammatory 
Markers 
          

















10.8  26.2  
N=19 
10.1  24.2  
N=29 









0.39  5.1  
N=17 
0.42  5.3  
N=28 





32.8  102.8  
N=18 
23.9  107.9  
N=29 





 43  
N=19 







11  23%  5  25%  6  21%  0.74 
Serum uric acid 5.6  1.7  6.4  1.9  5.0  1.4  0.02 
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1100  3161  
N=14 
953  3350  
N=25 






2321  4215  
N=14 
2642  3512  
N=25 





10,54  29  
N=19 
10,84  10  
N=28 
10,38  0.04 
aStudent’s t-test with unequal variances for normally distributed continuous measures, Wilcoxon 
Rank sum for non-normally distributed continuous measures, Fisher’s exact test for categorical 
measures 
bDefined as BMI ≥85th percentile 
c Defined as having ≥3 of the following: systolic or diastolic BP ≥90th percentile; BMI >97th 
percentile; triglycerides >110 mg/dL; HDL <40 mg/dL; waist circumference >90th percentile for 
boys, ≥90th percentile for girls59.   
Abbreviations: BMI=body mass index; HDL=high-density lipoprotein cholesterol; hsCRP=high 
sensitivity C-reactive protein; HTN=hypertension; IQR=interquartile range; LVH=Left Ventricular 














Table 11b. Baseline Clinic Blood Pressure, 24-hour Ambulatory Blood Pressure and Related 
Measures in Children with and without Left Ventricular Hypertrophy 
Characteristic 
Mean (SD), Median 
(IQR) or n (%) 
Overall  LVH 
N=20 























Systolic BP           
Clinic Systolic BP 
(mmHg) 
122  11.7  121  
N=11 
12.3  123  
N=24 
11.7  0.69 




0.08  0.93  
N=11 
0.08  0.98  
N=24 
0.08  0.1 
Awake Systolic BP 
(mmHg) 
128 10.9  126  
N=18 
9.4  129  
N=27 
11.8  0.34 




0.08  0.95  
N=18 
0.06  0.99  
N=27 
0.09  0.11 
24-hour Systolic BP 
(mmHg) 
123 10.5  122  
N=18 
9.9  124  
N=27 
11  0.63 




0.07  0.97  
N=18 
0.07  0.99  
N=27 
0.08  0.32 
Systolic Dipc (%) 9.7  
 
5.5  9.3  
N=17 
4.1  10.0  6.3  0.68 
Diastolic BP           




9.6  75 
N=11 
10.8  73 
N=24 
9.2  0.59 




0.11  0.89  
N=11 
0.14  0.89 
N=24 
0.1  0.98 
Awake Diastolic BP 
(mmHg) 
72  7.9  70  
N=18 
7.1  73  
N=27 
8.3  0.15 




0.1  0.85  
N=18 
0.09  0.89  
N=27 
0.1  0.11 




7.3  66  
N=18 
7.4  68  
N=27 





0.1  0.86  
N=18 
0.1  0.89  
N=27 
0.09  0.29 
Diastolic Dipc (%) 15.4  
 
11.4  13.7  
N=17 
7.3  16.5  
N=27 
13.2  0.37 
Pulse Pressure           
Clinic Pulse Pressure 49.1  9.4  46.5  
N=11 
12.4  50.3  
N=24 







7.8  56.4  
N=18 
8.6  56.1  
N=27 
7.5  0.89 
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BP Control           
Systolic and Diastolic 




60%  13  
N=18 
72%  14 
N=27 
52%  0.22 
Hormonal 
Regulators of BP 
















• On ACEi/ARB 10.73  5.36, 
18.95 









• Not on ACEi/ARB 2.89  1.35, 
3.78 













1,6  3  
N=20 
2,6  2.5 
N=28 
1,7  0.47 
• On ACEi/ARB 2  
 
0.5, 6  2  
N=13 





• Not on ACEi/ARB 4  2,6  4  
N=7 





aStudent’s t-test with unequal variances for normally distributed continuous measures, Wilcoxon 
Rank sum for non-normally distributed continuous measures, Fisher’s exact test for categorical 
measures 
bBPi=BP index; defined as the measured BP/95th percentile BP for age/sex/height; value ≥1 
denotes BP ≥95th percentile. 
cBP Dip=1- (BP during sleep/BP while awake)*100% 
Abbreviations: ACEi=angtiotensin converting enzyme inhibitor; ARB=angiotensin II receptor 
blocker; BP=blood pressure; IQR=interquartile range; LVH=Left Ventricular Hypertrophy; 







Table 12. Association of Baseline Characteristics, Change in Baseline Characteristics and 
Change in Left Ventricular Mass Index, Adjusted for Age, Sex and Race 
 Baseline Variables  Delta Variablesa 














Demographics        
Age (years) 1.01 0.37, 1.64 0.003     
Race (AA vs. non-AA) -0.10 -5.20, 5.0 0.97     
Sex (Male vs. Female) 0.08 -4.98, 5.14 0.97     
Measures of Adiposity        
BMI z-score 2.57 -0.04, 5.18 0.053  3.75 -4.23, 11.73 0.35 
Overweight/Obesec 4.44 0.49, 9.37 0.08     
Waist Circumference 
(cm) 
0.21 0.06, 0.36 0.008  0.18 -0.25, 0.61 0.40 
Blood Pressure        
Awake Systolic BPid -1.04 -32.02, 29.9 0.95  11.8 -20.6, 44.17 0.46 
Awake Diastolic BPid -17.39 -40.33, 5.56 0.13  -1.21 -26.5, 24.09 0.92 
Awake Pulse Pressure 0.38 -0.002, 0.77 0.051  0.14 -0.14, 0.42 0.32 
Hormonal Regulators 
of BP 
       
Serum aldosterone 
(ng/dL) 
-0.05 -0.25, 0.16 0.65  0.03 -0.17, 0.22 0.78 
Plasma renin activity 
(ng/mL/h) 
0.14 -0.04, 0.32 0.12  -0.02 -0.16, 0.12 0.81 
Inflammatory Markers        
hsCRP (mg/L) -0.66 -2.26, 0.94 0.40  0.56 -0.35, 1.48 0.22 
25-OH Vitamin D 
(ng/mL) 
0.13 -0.13, 0.39 0.3  -0.26 -0.53, 0.003 0.053 
Markers of Metabolic 
Dysregulation 
       
Hemoglobin A1c (%) -5.79 -12.60, 1.01 0.09  5.54 0.29, 10.78 0.039 
Non-HDL cholesterol 
(mg/dL) 
-0.03 -0.12, 0.05 0.4  0.03 -0.09, 0.16 0.59 
Lipoprotein (a) 
(nmol/L) 
-0.008 -0.04, 0.019 0.55  0.01 -0.05, 0.07 0.75 
Serum Uric Acid 
(mg/dL) 
0.30 -1.79, 2.4 0.77  -0.20 -4.28, 3.88 0.92 
Dietary Risk Factors 
and Markers of 
Intravascular Volume 












0.019 -0.05, 0.08 0.56  -0.05 -0.12, 0.03 0.24 
aDelta Variables are the change values for each characteristic listed.  They represent the 
difference in measurement between the two study visits (value at 12-month follow-up – value 
at baseline).  Δ represents a delta variable.   
bEach characteristic individually assessed in a separate model that adjusted for age, sex and 
race. 
cDefined as BMI ≥85th percentile  
dBPi=BP index; defined as measured BP/95th percentile BP for age/sex/height; value ≥1 denotes 
a BP ≥95th percentile. 
Abbreviations: AA=African American; ACEi=angtiotensin converting enzyme inhibitor; 
ARB=angiotensin II receptor blocker; BMI=body mass index; BP=blood pressure; HDL=high-
density lipoprotein cholesterol; hsCRP=high sensitivity C-reactive protein; LVMI=left ventricular 





Table 13. Association of Baseline Body Mass Index z-score with Change in Left Ventricular 
Mass Index – Investigating for Mediating Pathway 
Multivariable 
Models 
Adjusting for the following 
variables: 







Model 1 Age, race, sex 2.57 -0.04, 5.18 0.053 
Model 2  
(Base Model) 
Age, race, sex, LVMI at baseline 4.08 1.54, 6.61 0.002 
Blood Pressure:     
Model 3a  Model 2 covariates + Awake SBPia 
at baseline and follow-up  
3.86 1.25, 6.47 0.005 
Metabolic 
Dysregulation: 
    
Model 3b Model 2 covariates + non-HDL 
cholesterol at baseline and 
follow-up 
3.72 1.09, 6.35 0.007 
Model 3c Model 2 covariates + Hemoglobin 
A1c at baseline and follow-up 
3.94 1.43, 6.45 0.003 
Inflammation:     
Model 3d Model 2 covariates + hsCRP at 
baseline and follow-up 
4.21 1.40, 7.02 0.004 
Model 3e Model 2 covariates + 25-hydroxy 
vitamin D at baseline and follow-
up 




    
Model 3f Model 2 covariates + serum 
aldosterone at baseline and 
follow-up 
4.15 1.55, 6.76 0.003 
Model 3g Model 3f covariates + ACEi/ARB 
use at baseline and follow-up 




    
Model 3h Model 2 covariates + pulse 
pressure at baseline and follow-
up 
3.17 0.26, 6.07 0.03 
aSBPi= systolic blood pressure index, defined as awake SBP/95th percentile awake SBP.   
Abbreviations: ACEi=angiotensin converting enzyme inhibitor; ARB=Angiotensin II Receptor 
Blocker; BMI=body mass index; hsCRP=high sensitivity C-Reactive Protein; LVMI=Left Ventricular 




Chapter 5: Conclusions 
This thesis research describes the breadth and significance of pediatric hypertension 
and how this previously adult-predominant condition has now solidified itself as a common 
pediatric problem.  While the reported prevalence of diagnosed hypertension has increased to 
one in 25 children3, this may be an underestimate.  We have previously shown that provider 
recognition of elevated blood pressure in children cared for in a primary care setting is 
exceedingly poor22 and others have shown provider adherence to recommended blood pressure 
screening to be less than optimal21.  Further, we have also shown that a substantial proportion 
of children with incident hypertension already have evidence of target organ damage in the 
form of left ventricular hypertrophy (LVH) at initial diagnosis and that the severity of their 
hypertension is not associated with its presence9.  These studies suggest that elevated blood 
pressure detection and hypertension diagnosis in children may be delayed or that other factors, 
specifically obesity, also has a more substantial role in the development of target organ damage, 
specifically LVH, among hypertensive children. 
To further expand on our prior work we conducted two separate studies.  The first study 
determined the impact of an intervention combining education and technology on provider 
recognition of elevated blood pressure in a pediatric primary care clinic.  In the second study, we 
examined the longitudinal association of obesity and obesity-related risk factors with LVH and 
left ventricular mass in children with hypertension.   
During implementation of our intervention, recognition of elevated blood pressure 
increased more than three-fold (12.5% to 42%, p<0.001), but still remained poor with more than 
half of elevated blood pressure encounters remaining unrecognized.  We were surprised to find 
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that recognition was no different by educational session attendance status, but unsurprised to 
discover that recognition was lower during acute care encounters when compared to scheduled 
clinic encounters (prevalence ratio (PR) 0.6, 95% confidence interval (CI) 0.5- 0.7; p<0.001).  
Encounters of children with a co-morbid CVD risk factor or more obviously elevated blood 
pressure were more likely to be recognized in both the pre-intervention and intervention 
periods.  However, after implementation of automated alerts, recognition was less influenced 
by the presence or absence of these risk factors.   
 In our prospective, observational study of children with established hypertension, we 
found a high prevalence of co-morbid cardiovascular disease (CVD) risk factors.  More than half 
of the children were overweight/obese and 41% had LVH.   These CVD risk factors, in addition to 
serum uric acid, lipids, hemoglobin A1c, and hsCRP, increased or worsened over time despite 
relatively good BP control.    
Children who were overweight or obese at both study visits experienced the greatest 
increase in left ventricular mass index (LVMI) over time: mean change in LVMI was 6.4 g/m2.7 
(95% CI 2.4, 10.5) among those overweight or obese at each visit, vs. 0.95 g/m2.7 (95%CI -3.2, 
5.1) among children who were of healthy weight at each visit (p=0.056).  Overweight/obese 
children with and without LVH at baseline demonstrated a larger increase in LVMI compared to 
healthy weight children.  In fact, healthy weight children with LVH were the only ones with 
decreased LVMI over time.  
We also demonstrated that baseline BMI z-score was positively associated with an 
increase in LVMI over time (β 4.08, 95% CI 1.54, 6.61, p=0.002) during multivariable regression 
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analyses adjusting for age, sex, race, and LVMI at baseline.  This association remained essentially 
unchanged after sequential adjustment for all postulated mediating pathways between BMI z-
score and LVMI, with the exception of pulse pressure and serum aldosterone.  When added to 
the model, those two risk factors decreased the point estimate, suggesting they were partial 
mediators of this relationship.  The strong relationship between BMI z-score and change in LVMI 
that persisted despite adjusting for each of these factors suggests either an independent 
relationship between adiposity and LVMI or, more likely, an interaction of LVMI with many or all 
of these mediators.   
Overall, our work documents a substantial burden of CVD risk factors among our most 
vulnerable population – children and adolescents.  It has been estimated that at least 24.5 
million of the 74.2 million children in the United States4 have one or more CVD risk factor, which 
include diagnoses such as hypertension, dyslipidemia and obesity.  These estimates rely on 
proper identification and diagnosis conducted in a busy clinical practice.  As we have shown, 
even with education and real-time electronic alerts, pediatricians under-recognize elevated 
blood pressure in routine practice.   This finding suggests that current population estimates may 
also underestimate the prevalence of pediatric hypertension nationally. 
A common underlying theme to this increased CVD risk is overweight and obesity.  The 
prevalence of hypertension in children has increased over the last several decades along with 
the known substantial increase in overweight and obesity among youth6.  In addition, all of the 
CVD risk factors screened for in children have known biological pathways associating them with 
increased body mass.  Our work shows that hypertensive children referred for subspecialty care 
demonstrate not only a high prevalence of co-morbid CVD risk factors at baseline, but an 
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increase in both their prevalence and severity over time.   Most striking of these CVD risk factors 
is the presence and substantial degree of overweight and obesity.  In fact, among the 
hypertensive children in our study, adiposity as determined by body mass index z-score was the 
greatest risk factor for both LVH and change in LVMI over time.  LVH, a form of target organ 
damage in hypertension defined by a LVMI ≥95th percentile, has been thought to occur via 
exposure to increased LV afterload as seen in hypertension.  In our study, no measure of blood 
pressure was associated with its presence.  Additionally, none of the measures of inflammation 
or metabolic dysregulation played an important mediating role between adiposity and LVMI 
over time.  Markers of intravascular volume and hormonal regulation of blood pressure did 
appear to partially mediate this relationship.  With these risk factors potentially modifiable by 
diet – specifically with sodium restriction – this finding emphasizes the importance of lifestyle 
modification in the treatment of hypertension in children.     
While not surprising that adherence to a heart healthy lifestyle, one that includes good 
diet quality and regular physical activity, would improve a child’s CVD risk profile, adherence 
remains a challenge.  Our work also shows that despite standard of care counseling regarding 
lifestyle modifications, the hypertensive children enrolled gained weight over time and 
manifested an increase in CVD risk factors despite good blood pressure control.  In addition, 
overweight and obese hypertensive children experienced greater increases in their left 
ventricular mass over time when compared to healthy weight counterparts.  And of the children 
who should have demonstrated a decrease in LVMI over time – those with LVH – only those with 
healthy weight met this therapeutic goal. 
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With the significant burden of CVD risk factors in children and the now well recognized 
tracking of hypertension and CVD risk factors from childhood to adulthood, primordial and 
primary prevention remains of paramount importance.  With overweight and obesity a common 
denominator for many if not all of these risk factors, we must find ways to engage and empower 
youth to follow a heart healthy lifestyle.  Primordial prevention remains the cornerstone of 
efforts to improve not only the CV health of our children and adolescents, but also decrease CVD 
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Furth, S, Warady, B, Mitsnefes, M.  Carotid Intima Media Thickness (cIMT) in 
Children with Chronic Kidney Disease (CKD): Results from the Chronic Kidney 
Disease in Children (CKiD) cohort study.  Poster presentation at the American 
Society of Nephrology Annual Meeting, November 2010. 
 
18. *Loeffler, L, Miller, E, Brady, T, Fadrowski, J. Uric Acid Level and Hypertension 
in U.S. Adolescents.  Platform Presentation at the American Society of 
Nephrology Annual Meeting, November 2010. 
 
19. *Pruette, CS, Fivush, B, Flynn, J, Brady, TM.  Left Ventricular Hypertrophy 
(LVH) Among African-American (AA) and Non-AA Children with Primary 
Hypertension (PHTN).  Clinical and Translational Science 4: P23, 2011. 
 
20. *Kogon, A, Pierce, C, McDermott, K, Brady, T, Mitsnefes, M, Warady, B, 
Furth, S, Flynn, J.  Factors Associated with Longitudinal Blood Pressure 
Changes in Pediatric Patients with Chronic Kidney Disease.  Platform 
Presentation at the American Society of Pediatric Nephrology Annual 
Meeting, May 2011.   
 
21. *Pruette, C, Fivush, B, Flynn, J, Brady, T.  Left Ventricular Geometry in 
Children with Primary Hypertension: Prevalence and Predictors.  Poster 
Presentation at the American Society of Hypertension Annual Meeting, May 
2011.  
 
22. *Kogon, A, Pierce, C.B., Brady, T.M., Mitsnefes, M, Warady, B.A., Furth, S.L., 
Flynn, J.T. Factors Contributing to the Development and Control of Elevated 
Blood Pressure in Pediatric CKD Patients.  Oral abstract presentation at the 
American Society of Nephrology Annual Meeting, November 2011.   
 
23. *Brady, T.M., Neu, A.M., Siberry, G., Solomon, B. Increased Provider 
Recognition of Elevated Blood Pressure in Children.  Poster Presentation at 
the American Society of Nephrology Annual Meeting, November 2012.   
 
24. *Reader, L.D., Fadrowski, J.J., Loeffler, L.F., Miller, E.R., Holmes, K.W., Brady, 
T.M. Association of Uric Acid and Left Ventricular Hypertrophy in Pediatric 
Hypertension. Oral Poster Presentation, Medical Student Research Day, 




25. *Brady, T.M., Holmes, K.W., Boynton, S., Pruette, C., Fadrowski, J.J., 
Miller,E.R. Diurnal Blood Pressure (BP) and BP Variability is not associated 
with Left Ventricular Hypertrophy among Hypertensive Children. Poster 
Presentation at the American Society of Pediatric Nephrology Annual 
Meeting, May 2013.  
 
26. *Reader, L.D., Fadrowski, J.J., Loeffler, L.F., Miller, E.R., Holmes, K.W., Brady, 
T.M. Association of Uric Acid and Left Ventricular Hypertrophy in Pediatric 
Hypertension. Poster Presentation at the American Society of Pediatric 
Nephrology Annual Meeting, May 2013. 
 
27. *Thompson W.R., Holmes K.W., Jennings J., Brady T.M.  Ventricular Strain is 
Abnormal in Children with Hypertension.  Poster Presentation at the 
American Heart Association Scientific Sessions Meeting, November 2013. 
 
28. *T. Brady, K. McDermott, M. Schneider, C. Cox, B. Warady, S. Furth, M. 
Mistnefes.  Cystatin C Independently Predicts Change in Left Ventricular 
Mass index Over Time in Children with Chronic Kidney Disease.  Journal of 
the American Society of Nephrology 24: 430A, 2013. 
 
29. *T. Brady, K. McDermott, M. Schneider, C. Cox, B. Warady, S. Furth, M. 
Mistnefes.  Cystatin C Independently Predicts Abnormal Systolic and Diastolic 
Function Over Time in Children with Chronic Kidney Disease (CKD). Platform 
Presentation at the American Society of Pediatric Nephrology Annual 
Meeting, May 2014. 
 
30. C.S. Pruette, T.M. Brady, S. Mendley, B. Fivush, D. Roter, A. Green, K. Riekert. 
Patient-Provider Communication on Medication Adherence in Adolescents 
with Chronic Kidney Disease. Submitted to the American Society of Pediatric 
Nephrology Annual Meeting, May 2014. 
 
31. *Reader, L.D., Fadrowski, J.J., Loeffler, L.F., Miller, E.R., Holmes, K.W., Brady, 
T.M. Uric Acid Is Not Associated With Change In Left Ventricular Mass Index 
Among Hypertensive Children. Poster Presentation at the American Society 
of Pediatric Nephrology Annual Meeting, May 2014. 
 
32. Habli, M., Brady, T.M., Eschenbacher, M., Rodriguez, Z., DeFranco, E.A., 
Kamath-Rayne, B.D. Neonatal Hypertension and Antenatal Exposure to 
NSAIDs. Submitted to the American Society of Nephrology Annual Meeting, 
November 2014.  
 
33.  Pruette, C.S., Brady, T.M., Mendley, S., Fivush, B., Roter, D., Green, A., Eakin, 
M.A., Riekert, K.A. Medication Adherence in Adolescents with Chronic Kidney 
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Disease or Kidney Transplantation: Self- Report Vs. Provider Perception. 
Submitted to the American Society of Nephrology Annual Meeting, 
November 2014.  
 
34. Sethna, C.B., Mariani, L.H., Weyant, R.J., Brady, T.M., Meyers, K.E.C., Gibson, 
K.L., Wickman, L.T., Gadegbeku, C.A. Hypertension and Blood Pressure 
Variability in NEPTUNE. Submitted to the American Society of Nephrology 
Annual Meeting, November 2014. 
 
35. Brady, T.M., Fivush, B., Holmes, K., Miller, E.R. The Relationship between 
Adiposity and Left Ventricular Mass in Children with Hypertension.  
Submitted to the American Society of Nephrology Annual Meeting, 
November 2014. 
 




2002   American Society of Pediatric Nephrology Travel Grant 
Awarded to attend the American Society of Nephrology Annual 
Meeting and Exhibition 
Philadelphia, PA 
 
2003   American Society of Pediatric Nephrology Travel Grant 
Awarded to attend the American Society of Nephrology Annual 
Meeting and Exhibition 
San Diego, CA 
 
2003   American Society of Pediatric Nephrology Travel Grant 




8/1/2004-  NIH/NIDDK 
6/30/2005  T32 DK07732 
Renal Disease Epidemiology Training Grant 
PI:  Michael J. Klag, MD, MPH 
   Role: Pediatric Nephrology Fellow 
   $45,048 
 
2005   Eastern Society for Pediatric Research Travel Grant   




Old Greenwich, CT 
 
7/1/2005-  NIH/NIDDK 
6/30/2006  T32 DK07732 
Renal Disease Epidemiology Training Grant 
PI:  Michael J. Klag, MD, MPH 
   Role: Pediatric Nephrology Fellow 
$46,992  
 
2006   National Kidney Foundation Travel Grant 




7/1/2006-  Prospective Study of Barriers Impeding Recognition    
6/30/2007  of Elevated Blood Pressure in Children   
National Kidney Foundation of Maryland 
   Mini-Grant Award 
   Role: Principal Investigator 
$5,400 
 
7/1/2006-  Prospective Study of Barriers Impeding Recognition   
6/30/2008  of Elevated Blood Pressure in Children  
American Kidney Fund Clinical Scientist in Nephrology 
   Fellowship Award 
Role: Pediatric Nephrology Fellow, Principal Investigator 
$113,500 
 
7/1/2006-  Prospective Study of Barriers Impeding Recognition   
6/30/2008  of Elevated Blood Pressure in Children  
National Institutes of Health 
   Loan Repayment Program Award 
$70,000 
 
7/1/2008–  Longitudinal Study of Left Ventricular Hypertrophy 
6/30/2009  Regression in Children with Primary Hypertension 
   National Kidney Foundation of Maryland 
   Professional Development Award 
   Role: Principal Investigator 
$40,000 
 
7/1/2008-  Longitudinal Study of Left Ventricular Hypertrophy 
6/30/2009  Regression in Children with Primary Hypertension 
 
 94 
   Thomas Wilson Sanitarium for the Children of Baltimore City  
   Grant Award 
   Role: Principal Investigator 
$20,000 
 
7/1/2008 –   Improving the Diagnosis and Treatment of Children 
6/30/2009  with Elevated Blood Pressure and Hypertension 
Johns Hopkins Children’s Center  
Special Studies Project 
$9,970 
 
9/1/2008 –   Longitudinal Study of Left Ventricular Hypertrophy 
8/30/2011  Regression in Children with Primary Hypertension 
American Society of Nephrology  
Norman Siegel Research Scholar Grant  
Role: Principal Investigator 
$180,000 direct support 
 
9/1/2010 –   National Institutes of Health/ Johns Hopkins Institute 
8/31/2012  for Clinical and Translational Research 
   KL2 Clinical Research Scholar Award 
5KL2RR025006 
$130,000 annual direct support 
 
7/1/2011 –   Empowering and Enabling Hypertensive Children and 
6/30/2012  Families to Improve their Health 
Johns Hopkins Children’s Center  
Special Studies Project 
$10,000 
 
1/1/2011-  Metabolic Determinants of Left Ventricular Mass in 
12/31/2012  Children with Primary Hypertension 
   American Heart Association 
   Clinical Research Program 
   11CRP5270013 
   $50,000 annual direct support 
 
7/1/2011-  Metabolic Determinants of Left Ventricular Mass in 
6/30/2013  Children with Hypertension  
National Institutes of Health 







9/1/2011 –   Doctor-Teen Communication & Antihypertensive 
5/31/2016      Adherence among Teens with CKD 
NIH NIDDK  
R01DK092919 
Total Costs= $2,231,744 
P.I. Kristin Riekert, PhD 
Role: Co-investigator 
 
7/1/2013-  Feasibility of a Texting Intervention among Children   
6/30/2014  and Young Adults 
   National Kidney Foundation of Maryland  
   Mini-Grant Award 
   Role: Principal Investigator 
$10,000 
 
1/1/2014-  Clinician Scientist Award 
12/30/2014  Johns Hopkins University School of Medicine 




7/1/2014-  Promoting Heart Healthy Behaviors in Youth 
6/30/2018  NIH NHLBI 
   1K23 HL119622-01 
   Total Direct Costs=$743,445 
   Role: Principal Investigator 
 
III. CLINICAL ACTIVITIES 
 
A.  Licensure and certification 
 
Medical License 2002 – State of New York, License No. 228732 
   2004 – District of Colombia, License No. MD035032 
   2004 – State of Maryland, License No. D0062035 
 
Board Certifications ’03, ’13 - Diplomate, American Board of Pediatrics 
‘10   - Diplomate, American Board of Pediatrics, Sub-board 






B.  Service Responsibilities 
  
2008 – Present Pediatric Nephrology Attending/Consult Service 
8-12 Weeks/Year 
 
2008 – Present Harriet Lane Kidney Center Outpatient Clinic 
2 Half-day Sessions/Month 
 
2008 – Present Harriet Lane Kidney Center Hypertension Clinic 
   1 Half-day Session/Month 
 
C.  Clinical Program Building 
 
2011 – Present Pediatric Hypertension Program 
   Medical Director 
Develop and oversee a multi-disciplinary pediatric hypertension 
clinic which provides specialized renal nursing and dietician 
services.  This clinic provides a comprehensive evaluation and 
treatment approach that includes the use of 24-hour ambulatory 
blood pressure monitoring, echocardiography interpretation, 
obstructive sleep apnea screening, home blood pressure monitors 
and weight loss support.  Pediatric focused educational materials 
and support for successful lifestyle modifications are provided.    
  
 
IV. EDUCATIONAL ACTIVITIES 
 
A. Clinical Instruction 
 
2003-2004  Morning Conference – 3 conferences/ year  
Responsible for presenting didactic lectures to housestaff and 
medical students on core topics in pediatrics 
 
2003-2004  Weekly medical student walk rounds 
Pediatric Ward Teams 
   Responsible for case-based teaching of medical students 
 
2003-2004  Chairman’s Rounds 
Once per week 






2003-2004  Professor’s Walk Rounds 
Twice per week 
Responsible for preparing presentation for housestaff and medical 
students 
 
2003-2004  Mock Codes 
4 times per month 
Responsible for preparing and running mock code for housestaff 
and medical students 
 
2005-2008  Board Review  
   4-6 times per year 
Responsible for preparing and giving lectures on relevant 
nephrology topics for pediatric residents and pediatric nephrology 
fellows 
 
2006   Renal Physiology Course Small Group Leader 
   2 hour session 
   First-year Medical Students 
 
2007, 2009  Harriet Lane Clinic 
   Continuity Clinic Lecture Series 
   Lecture – “Pediatric Hypertension” 
   Johns Hopkins University  
Baltimore, MD 
  
2008 – Present Pediatric Nephrology Attending Teaching Rounds 
   8-12 weeks per year 
Responsible for 1-2 hour teaching rounds daily for residents  
 
2008 – Present Nephrology Rotation Core Lecture Series 
   1 lecture/month 
Pediatric Housestaff 
 
2009, 2011  Pediatric Noon Clinical Conference 
“Hypertensive Urgencies and Emergencies in Children – 
Assessment and Management” 
Johns Hopkins University 
   Baltimore, MD 
 
2009   Pediatric Noon Clinical Conference 




   Baltimore, MD 
 
2009   Pediatric Noon Clinical Conference 
“Nephrotic Syndrome” 
Johns Hopkins University 
   Baltimore, MD 
 
2010   Pediatric Noon Clinical Conference 
“Renal Tubular Acidosis” 
Johns Hopkins University 
   Baltimore, MD 
 
2010, 2013  Neonatal Intensive Care Unit Lecture Series 
“Neonatal Hypertension” 
Johns Hopkins University 
   Baltimore, MD 
 
2012   Emergency Department Lecture Series 
“Hypertensive Crises” 
Johns Hopkins University 
   Baltimore, MD 
 
2012-2014  Pediatric Intensive Care Unit Lecture Series 
“Hypertensive Crises” 
Johns Hopkins University 
   Baltimore, MD 
 
2012, 2013  Clinical Epidemiology Course – Small Group Leader 
   First Year Medical Students 
Johns Hopkins University School of Medicine 
   Baltimore, MD 
 
B.  CME Instruction  
 
2006   Pediatric Trends  
   “Chronic Kidney Disease Presenting as Constipation” 
Johns Hopkins University 
Baltimore, MD 
 
2006   Pediatric Case Management Conference 
   “Obstructive Uropathy” 
Johns Hopkins University 




2007    Platform Presentation  
“Prevalence and Predictors of Unrecognized High Blood Pressure 
in Children” 
   American Society of Pediatric Nephrology Annual Meeting 
Toronto, Canada 
 
2008   Pediatric Trends 
“Vesicoureteral Reflux Presenting as Fever and Malaise” 
Johns Hopkins University 
   Baltimore, MD 
 
2008   Pediatric Noon Research Conference 
“Pediatric Hypertension: Patient Characteristics, Target Organ 
Damage and Effectiveness of BP Screening” 
Johns Hopkins University 
   Baltimore, MD 
 
2010    Oral Poster Presentation 
“Correlates of carotid artery intima media thickness in children 
with Chronic Kidney Disease: a report from the Chronic Kidney 
Disease in Children (CKiD) cohort study.”   
The Fifteenth Congress of the International Pediatric Nephrology 
Association 
   New York, NY 
 
2013   Pediatric Trends  
   “Hypertensive Crisis” 
Johns Hopkins University 
Baltimore, MD 
 
C.  CME Instruction, Alternative Media 
 
2008  Brady, TM, Siberry, G, Solomon, B.  Pediatric Hypertension: A 
Review of Proper Screening, Diagnosis, Evaluation and Treatment. 
Contemporary Pediatrics 25(11): 46-56, 2008. CME activity. 
 





2009-2012  Cozumel Pruette, MD, MHS 
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   Assistant Professor Pediatrics 
2012 Recipient of the Francis Schwentker Award for Excellence in 
Research, based on the manuscript “Effects of Obesity and Race 
on Left Ventricular Geometry in Hypertensive Children”.   
 
2010-2012  Darcy Weidemann, MD 
   Pediatric Nephrology Fellow 
   Resident QI Project  
   Elevated BP Recognition in a Primary Care Setting 
 
2012-present  Lauren Reader 
   Medical Student (M’15) 
   Johns Hopkins University School of Medicine 
Scholarly Concentration Project: “Association of Uric Acid and Left 
Ventricular Hypertrophy in Pediatric Hypertension” 
Research abstract selected for Oral Presentation at Medical 
Student Research Day and as a Poster Presentation at the 
American Society of Pediatric Nephrology annual meeting  
 
V.  ORGANIZATIONAL ACTIVITIES 
 
A.  University and Hospital Committees / Positions Held / Sub-Committees 
 
1. Children’s Hospital at Montefiore 
 
2003 – 2004  Representative, Radiology Task Force 
 
2003 – 2004 Children’s Hospital at Montefiore (CHAM) Quality Improvement 
Committee 
 
2003 – 2004  CHAM 8 & 9 Quality Performance Improvement Subcommittee 
 
2003 – 2004 Adolescent Inpatient Unit Quality Performance Improvement 
Subcommittee 
 
2003 – 2004   CHAM 8 & 9 Inpatient Review Committee 
 
2003 – 2004  Adolescent Inpatient Unit Review Committee   
 
2003 – 2004  Intern Selection Committee 
 




2005-Present  Advocacy Committee 
Participated in and helped organize several fund-raising and 
patient activities for the Johns Hopkins Department of Pediatric 
Nephrology.  
 
2008-Present  Fellow Applicant Selection 
Actively involved in interviewing applicants and selecting 
candidates for the Johns Hopkins Pediatric Nephrology Fellowship 
Program 
 
2012-Present   Pediatric Nephrology Division QI Project Co-Leader    
Responsible for designing, implementing and disseminating the 
results of the project: “Tracking and Improving Pneumococcal 
Vaccination Rates, January 1, 2013 through June 30, 2013”, 
followed by an expansion of the project to include all children 
with CKD, July 1, 2013 through June 30, 2014. 
 
3. Johns Hopkins University, Department of Pediatrics 
 
2006-2009  Computerized Alerts Committee 
Active participant involved in the conception, development, and 
testing of computerized alerts designed to notify providers of 
elevated blood pressure in the Harriet Lane Clinic. 
 
2012-Present   Intern Applicant Selection 
Actively involved in interviewing applicants and selecting 
candidates for the Johns Hopkins Pediatric Residency Program 
 
B.  Abstract Reviewer/ National Meetings 
 
2009, 2010  American Society of Nephrology Abstract Reviewer 
 
C.  Professional Affiliations/ Committees/ Positions Held/ Sub-Committees 
 
2000-04, ‘07-08,  American Academy of Pediatrics 
2013-Present    2013-Present: Section on Nephrology 
    2013-Present: PREP Nephrology Editorial Board 
 
2005-Present  American Society of Nephrology 
 
2005-Present  American Society of Pediatric Nephrology 
    2009-Present: Research Committee 




2005-Present  International Pediatric Hypertension Organization 
 
2008-2010  National Kidney Foundation 
     
2008-2011  Mid-Atlantic Renal Coalition 
2008-2011: Pediatric Nephrology Network Consortium 
 
2009-Present CKiD (Chronic Kidney Disease in Children) Cohort Study 
Consortium 
2009-Present: Cardiovascular Sub-Committee 
 
2010-2012  International Pediatric Nephrology Association 
 
2010-Present  American Kidney Fund 
   Clinical Scientist in Nephrology Committee 
 
2013-Present NEPTUNE (NEPhrotic Syndrome STUdy NEtwork) Pediatric 
Working Group 
    2013–Present: Cardiovascular Outcomes Committee 
    2013-Present: Recruitment and Retention Committee 
 
2014-Present  National Kidney Foundation of Maryland 
    Medical Advisory Board Member 
 
2014-Present  Association for the Advancement of Medical Instrumentation 




A.  Honors 
 
1992 - 1996  Dean’s List 
   Boston College, Chestnut Hill, MA 
 
1996   Magna Cum Laude 
Boston College, Chestnut Hill, MA 
 
1996   William J. Kenealy, S.J. Award 
Awarded for distinction in academics and social concern 
 
1996   Order of the Cross and Crown 
Awarded for high academic standing and an established record of 
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service and leadership on campus 
   
2003-2004  Chief Residency, Pediatrics 
   Children’s Hospital at Montefiore 
   Bronx, NY 
 
2006   Recipient of the Pearl M. Stetler Fellowship Award 
   Research funding for woman physician  
 
2007   American Society of Pediatric Nephrology  
Trainee Research Award 
Best Clinical Abstract 
 
2011   NEMA Research 
   Clinical Research Award 
Awarded to the individual in the Johns Hopkins Bloomberg School 
of Public Health GTPCI program with the highest score on the 
Comprehensive Exam  
 
2013   Super Doctors Rising Star 
   Washington, DC-Baltimore-Northern Virginia  
 
2013   Leadership Program for Women Faculty 
Selected as a participant in this highly regarded program designed 
to promote leadership development among women and academic 
medicine career building. 
 
B.  Invited Presentations/Lectures 
 
2004   Pediatric Grand Rounds 
“Common Pediatric Problems: What Should We Do?  An Evidence 
Based Medicine Approach” 
The Children’s Hospital at Montefiore 
Bronx, NY 
 
2006   Adult Nephrology Grand Rounds 
    “Challenging Pediatric Nephrology Cases” 
Johns Hopkins University  
   Baltimore, MD 
 
2007   Pediatric Grand Rounds 




Johns Hopkins University 
   Baltimore, MD 
 
2007   American Kidney Fund 
   Board of Trustees Meeting 
   Research Platform Presentation 
   Rockville, MD 
 
2008   Pediatrics for the Practitioner 
   “The Ups and Downs of Blood Pressure: Hypertension in Children” 
Johns Hopkins University 
   Baltimore, MD 
 
2009   Pediatric Grand Rounds 
   “Hypertension in Children” 
   Franklin Square Hospital Center 
   Baltimore, MD 
 
2009   Pediatric Grand Rounds 
   “Risk Factors for and Sequelae of Pediatric Hypertension” 
Johns Hopkins University 
   Baltimore, MD 
 
2009   Adult Nephrology Grand Rounds 
“Pediatric Hypertension: Further Evidence that Children are not 
Little Adults” 
Johns Hopkins University  
   Baltimore, MD 
 
2010   Pediatric Grand Rounds 
   “Pediatric Hypertension: Who is at risk?” 
Georgetown University Medical Center 
   Washington, DC 
 
 
2010   Pediatric Grand Rounds 
   “Pediatric Hypertension: Who is at risk?” 
Virginia Hospital Center 
   Arlington, VA 
   
2010   Pediatric Grand Rounds 
   “Pediatric Hypertension: Who is at risk?” 
Uniformed Services University of the Health Sciences  
 
 105 
   Bethesda, MD 
 
2011   Pediatric Trends 
“Pediatric Hypertension” 
Johns Hopkins University 
   Baltimore, MD 
 
2012   Pediatric Grand Rounds 
   “Hypertension in Children and Adolescents” 
St. Agnes Hospital 
   Baltimore, MD 
 
2012-2014  Pediatrics for the Practitioner 
   Session Workshop 
   “Hypertension” 
   Johns Hopkins University 
   Baltimore, MD 
 
2013   Pediatric Grand Rounds 
   “The Skinny on Obesity Related Hypertension in Children” 
Johns Hopkins University 
   Baltimore, MD 
 
2013   Pediatric Grand Rounds 
   “The Skinny on Obesity Related Hypertension in Children” 
   Sinai Hospital of Baltimore 
   Baltimore, MD 
 
2013    Dean’s Presentation   
   “Heart Health in Children with High Blood Pressure” 
   Johns Hopkins University 
   Baltimore, MD 
 
2013   Pediatric Grand Rounds 
   “The Skinny on Obesity Related Hypertension in Children” 
   Greater Baltimore Medical Center 
   Baltimore, MD 
 
2013   American Society of Pediatric Nephrology 
Workshop: "Urine the Know" Best of Pediatric Nephrology in 
2012-2013 
“Carotid intima-media thickness in children with CKD: results from 
the CKiD study” 
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   Washington, DC     
     
2013   Student Health and Wellness Center 
   “Adolescent Hypertension” 
   Johns Hopkins University 
   Baltimore, MD 
 
C.  Editorial Appointments 
 
1. Clinical Guideline Review Activities 
 
2011 Kidney Disease: Improving Global Outcomes (KDIGO) - “KDIGO 
Clinical Practice Guideline for Management of Blood Pressure in 
CKD.” 
 
2. Journal Peer Review Activities     
 
2014 - Present  Frontiers in Pediatric Nephrology 
Review Editorial Board 
Review Editor 
    
2008 - Present  Reviewer for:  
• Pediatrics      
• Journal of Human Hypertension 
• American Journal of Hypertension 
• Clinical Journal of the American Society of Nephrology 
• Pediatric Transplantation 
• International Journal of Pediatrics 
• Pediatric Cardiology 
• Nutrition, Metabolism & Cardiovascular Diseases  
• Pediatric Anesthesia 
• Medical Science Monitor 
   
3. Book Chapter Review Activities 
 
2009   First Aid for the USMLE Step 2 Clinical Knowledge 
7th edition 
Renal/Genitourinary chapter  
 
D.  Media 
 
1. “High Blood Pressure Affecting Children Now.”  WJZ Baltimore.  May 19, 




2. “Missing a Threat to Young Hearts.”  Baltimore Sun.  June 1, 2009. 
 
3. “Kids Should Get Hypertension Checks, Too.”  WBALTV Baltimore.  June 2, 
2009.  http://www.wbaltv.com/video/19583272/index.html?taf=bal 
 




5. “Doctors Focus on Kids’ Blood Pressure.”  Wall Street Journal.  June 29, 2010. 
 
6. “High Blood Pressure in Children.”  WOLB 1010 AM. Urban Health Radio 
Program.  Breaking it Down: Our Health Our Way.  January 26, 2012 
 
7. “Johns Hopkins Expert Sees More Hypertension in Kids.”  USA Washington.  
September 17, 2012. 
http://www.wusa9.com/news/article/221855/28/Johns-Hopkins-Expert-
Sees-More-Hypertension-In-Kids 
 
 
